This project focuses on Analysis 2 of the Study Protocol, which aims to characterize pregnant individuals with OUD and examine hazards of maternal death and overdose. A poster was presented at Academy Health annual research meeting focusing on analysis on those with OUD and at least one day of MOUD prescription. (Section 7)
Data Source
Inclusion Criteria
Statistical analysis
Descriptive statistics were computed using frequencies (proportions) and medians (IQRs) as appropriate for the overall sample and also stratified by timing of MOUD receipt. Timing of MOUD receipt variable was categorized relative to timing of delivery and has two levels: receipt during one period only either pre- or post-delivery or receipt during both pre- and post-delivery periods. Due to the low number of outcomes, several variables were collapsed into one. These variables are listed below.
After calculating the number of days of MOUD receipt, various histograms were plotted to examine differences by method. Then, multivariable Cox Proportional hazards model were used to determine the associations between total days of MOUD receipt as the main exposure and death or overdose as the outcome. For individuals with multiple outcomes, the earliest outcome was used. Outcomes that occurred during the follow-up period were counted if they were captured in the TN all payer database if an individual lost eligibility for TennCare. Average dose per day of MOUD receipt (qty*dose)/(days supply) was also calculated and described in the table. Average days supply and dose from the pre-delivery period that exceeded 90 days was carried over and added to the post-delivery period.
The Cox model was first modeled using linear continuous terms, due to the limited degrees of freedom. However, year of delivery was determined to be non-linear and was modeled using a restricted cubic spline with 3 knots. These models included the following covariates: year of delivery, total day MOUD receipt, age at delivery, gestation weeks, route of delivery, combined pain conditions, alcohol/other substance use, benzodiazepine/anticonvulsant use, anxiety/depression, maternal morbidity (CDC defined). Additional covariates were included initially but were removed due to the small number of outcomes. These include race/ethnicity combined, number of previous pregnancies, schizophrenia/personality disorder, CDC social vulnerability index, and timing of MOUD receipt (one or two periods relative to delivery). Robust standard errors clustered at the individual level were computed.
Additonal notes: few outcomes (<5) prior to 2015
| N | Overall | |
|---|---|---|
| (N=9048) | ||
| Year of delivery | 9048 (100.00) | |
| Median (interquartile range) | 2016 (2014—2018) | |
| Range | 2007—2020 | |
| Age at delivery | 9048 (100.00) | |
| Median (interquartile range) | 27 (24—31) | |
| Range | 17—44 | |
| Number of Gestation weeks | 9048 (100.00) | |
| Median (interquartile range) | 39 (37—39) | |
| Range | 21—42 | |
| Race | 9048 (100.00) | |
| American Indian or Alaska Native | 21/9048 (0.23) | |
| Asian or Pacific Islander | 12/9048 (0.13) | |
| Black of African American | 242/9048 (2.67) | |
| Other or Unknown | 60/9048 (0.66) | |
| White | 8713/9048 (96.30) | |
| Hispanic : Not Hispanic | 9043 (99.94) | 8964/9043 (99.13) |
| Race/Ethnicity combined | 9048 (100.00) | |
| Hispanic | 79/9048 (0.87) | |
| Non-Hispanic Asian | 11/9048 (0.12) | |
| Non-Hispanic Black | 240/9048 (2.65) | |
| Non-Hispanic Other | 58/9048 (0.64) | |
| Non-Hispanic White | 8660/9048 (95.71) | |
| Route of delivery : Vaginal | 9048 (100.00) | 5876/9048 (64.94) |
| Number of previous pregnancies | 8886 (98.21) | |
| Median (interquartile range) | 2 (1—3) | |
| Range | 0—23 | |
| Final outcome | 9048 (100.00) | |
| Death | 39/9048 (0.43) | |
| Overdose | 109/9048 (1.20) | |
| Loss of enrollment | 1022/9048 (11.30) | |
| Censored | 7878/9048 (87.07) | |
| Final outcome (w/o all payer data) | 9048 (100.00) | |
| Death | 15/9048 (0.17) | |
| Overdose | 103/9048 (1.14) | |
| Loss of enrollment | 1052/9048 (11.63) | |
| Censored | 7878/9048 (87.07) | |
| Total days supplied MOUD | 9048 (100.00) | |
| Median (interquartile range) | 124 (81—132) | |
| Range | 1—132 | |
| Total days supplied MOUD before delivery | 9048 (100.00) | |
| Median (interquartile range) | 90 (60—90) | |
| Range | 0—90 | |
| Total days supplied MOUD after delivery | 9048 (100.00) | |
| Median (interquartile range) | 42 (14—42) | |
| Range | 0—42 | |
| Total days supplied MOUD (method 2) | 9048 (100.00) | |
| Median (interquartile range) | 132 (81—132) | |
| Range | 1—132 | |
| Total days supplied MOUD before delivery (method 2) | 9048 (100.00) | |
| Median (interquartile range) | 90 (60—90) | |
| Range | 0—90 | |
| Total days supplied MOUD after delivery (method 2) | 9048 (100.00) | |
| Median (interquartile range) | 42 (36—42) | |
| Range | 0—42 | |
| Total days supplied MOUD (method 3) | 9048 (100.00) | |
| Median (interquartile range) | 88 (43—111) | |
| Range | 1—132 | |
| Total days supplied MOUD before delivery (method 3) | 9048 (100.00) | |
| Median (interquartile range) | 61 (28—77) | |
| Range | 0—90 | |
| Total days supplied MOUD after delivery (method 3) | 9048 (100.00) | |
| Median (interquartile range) | 29 (12—40) | |
| Range | 0—42 | |
| Avg dose pre-delivery (mg) | 9048 (100.00) | |
| Median (interquartile range) | 13.93 (8.00—16.00) | |
| Range | 0.00—50.00 | |
| Avg dose post-delivery (mg) | 9048 (100.00) | |
| Median (interquartile range) | 10.45 (4.00—16.00) | |
| Range | 0.00—380.00 | |
| Avg dose exposure (mg) | 9048 (100.00) | |
| Median (interquartile range) | 14.07 (9.55—16.00) | |
| Range | 0.00—380.00 | |
| Total days buprenorphine before delivery (method 3) | 8816 (97.44) | |
| Median (interquartile range) | 62.00 (30.00—77.00) | |
| Range | 0.00—90.00 | |
| Total days buprenorphine after delivery (method 3) | 8816 (97.44) | |
| Median (interquartile range) | 30.00 (12.00—40.00) | |
| Range | 0.00—42.00 | |
| Total days supplied buprenorphine | 8816 (97.44) | |
| Median (interquartile range) | 89.00 (45.00—112.00) | |
| Range | 1.00—132.00 | |
| Avg dose BUP pre-delivery (mg) | 8816 (97.44) | |
| Median (interquartile range) | 13.89 (8.00—16.00) | |
| Range | 0.00—40.00 | |
| Avg dose BUP post-delivery (mg) | 8816 (97.44) | |
| Median (interquartile range) | 9.87 (4.00—16.00) | |
| Range | 0.00—42.67 | |
| Avg dose BUP exposure (mg) | 8816 (97.44) | |
| Median (interquartile range) | 14.00 (9.18—16.00) | |
| Range | 0.00—42.67 | |
| Type of MOUD | 9048 (100.00) | |
| Both | 139/9048 (1.54) | |
| Buprenorphine only | 8700/9048 (96.15) | |
| Naltrexone only | 209/9048 (2.31) | |
| Combined pain : Yes | 9048 (100.00) | 7201/9048 (79.59) |
| Schizophrenia or personality disorder : Yes | 9048 (100.00) | 676/9048 (7.47) |
| Alcohol or other substance use : Yes | 9048 (100.00) | 3996/9048 (44.16) |
| Benzodiazepine or anticonvulsant use : Yes | 9048 (100.00) | 1303/9048 (14.40) |
| Maternal morbidity : Yes | 9048 (100.00) | 636/9048 (7.03) |
| Anxiety and depression combined : Yes | 9048 (100.00) | 4085/9048 (45.15) |
| Back pain : Yes | 9048 (100.00) | 3197/9048 (35.33) |
| Med muscle relaxant use : Yes | 9048 (100.00) | 453/9048 (5.01) |
| Med NSAIDS : Yes | 9048 (100.00) | 5737/9048 (63.41) |
| Bipolar disorder : Yes | 9048 (100.00) | 914/9048 (10.10) |
| Depression : Yes | 9048 (100.00) | 3489/9048 (38.56) |
| Maternal morbidity : Yes | 9048 (100.00) | 636/9048 (7.03) |
| Med benzodiazepine use : Yes | 9048 (100.00) | 890/9048 (9.84) |
| Schizophrenia psychotic disorders : Yes | 9048 (100.00) | 542/9048 (5.99) |
| Tobacco use : Yes | 9048 (100.00) | 6267/9048 (69.26) |
| Dental pain : Yes | 9048 (100.00) | 348/9048 (3.85) |
| Alcohol use disorder : Yes | 9048 (100.00) | 560/9048 (6.19) |
| Other substance use : Yes | 9048 (100.00) | 3814/9048 (42.15) |
| Anxiety : Yes | 9048 (100.00) | 1766/9048 (19.52) |
| Fibromyalgia : Yes | 9048 (100.00) | 454/9048 (5.02) |
| Med anticonvulsant use : Yes | 9048 (100.00) | 497/9048 (5.49) |
| Personality disorder : Yes | 9048 (100.00) | 247/9048 (2.73) |
| CDC SVI overall percentile ranking of all 4 themes | 8459 (93.49) | |
| Median (interquartile range) | 0.58 (0.37—0.78) | |
| Range | 0.00—1.00 |
| N | No outcome | Had outcome | Test Statistic | |
|---|---|---|---|---|
| (N=8900) | (N=148) | |||
| Year of delivery | 9048 (100.00) | F1,9046=41.30, P<0.00013 | ||
| Median (interquartile range) | 2016 (2014—2018) | 2018 (2016—2019) | ||
| Range | 2007—2020 | 2007—2020 | ||
| Age at delivery | 9048 (100.00) | F1,9046=0.63, P=0.42663 | ||
| Median (interquartile range) | 27 (24—31) | 27 (25—31) | ||
| Range | 17—44 | 19—41 | ||
| Number of Gestation weeks | 9048 (100.00) | F1,9046=6.82, P=0.00903 | ||
| Median (interquartile range) | 39 (37—39) | 38 (37—39) | ||
| Range | 21—42 | 25—42 | ||
| Race | 9048 (100.00) |
Χ2 4=28.15, P<0.00012 |
||
| American Indian or Alaska Native | 20/8900 (0.22) | 1/148 (0.68) | ||
| Asian or Pacific Islander | 12/8900 (0.13) | 0/148 (0.00) | ||
| Black of African American | 237/8900 (2.66) | 5/148 (3.38) | ||
| Other or Unknown | 54/8900 (0.61) | 6/148 (4.05) | ||
| White | 8577/8900 (96.37) | 136/148 (91.89) | ||
| Hispanic : Not Hispanic | 9043 (99.94) | 8818/8895 (99.13) | 146/148 (98.65) |
Χ2 1=0.40, P=0.52892 |
| Race/Ethnicity combined | 9048 (100.00) |
Χ2 4=28.54, P<0.00012 |
||
| Hispanic | 77/8900 (0.87) | 2/148 (1.35) | ||
| Non-Hispanic Asian | 11/8900 (0.12) | 0/148 (0.00) | ||
| Non-Hispanic Black | 235/8900 (2.64) | 5/148 (3.38) | ||
| Non-Hispanic Other | 52/8900 (0.58) | 6/148 (4.05) | ||
| Non-Hispanic White | 8525/8900 (95.79) | 135/148 (91.22) | ||
| Route of delivery : Vaginal | 9048 (100.00) | 5780/8900 (64.94) | 96/148 (64.86) |
Χ2 1=0.00, P=0.98412 |
| Number of previous pregnancies | 8886 (98.21) | F1,8884=1.14, P=0.28553 | ||
| Median (interquartile range) | 2 (1—3) | 2 (1—3) | ||
| Range | 0—23 | 0—12 | ||
| Final outcome | 9048 (100.00) |
Χ2 3=9048.00, P<0.00012 |
||
| Death | 0/8900 (0.00) | 39/148 (26.35) | ||
| Overdose | 0/8900 (0.00) | 109/148 (73.65) | ||
| Loss of enrollment | 1022/8900 (11.48) | 0/148 (0.00) | ||
| Censored | 7878/8900 (88.52) | 0/148 (0.00) | ||
| Final outcome (w/o all payer data) | 9048 (100.00) |
Χ2 3=7236.62, P<0.00012 |
||
| Death | 0/8900 (0.00) | 15/148 (10.14) | ||
| Overdose | 0/8900 (0.00) | 103/148 (69.59) | ||
| Loss of enrollment | 1022/8900 (11.48) | 30/148 (20.27) | ||
| Censored | 7878/8900 (88.52) | 0/148 (0.00) | ||
| Total days supplied MOUD (method 3) | 9048 (100.00) | F1,9046=9.23, P=0.00243 | ||
| Median (interquartile range) | 88 (43—111) | 72 (30—106) | ||
| Range | 1—132 | 2—131 | ||
| Total days supplied MOUD before delivery (method 3) | 9048 (100.00) | F1,9046=5.25, P=0.02203 | ||
| Median (interquartile range) | 62 (29—77) | 53 (17—76) | ||
| Range | 0—90 | 0—89 | ||
| Total days supplied MOUD after delivery (method 3) | 9048 (100.00) | F1,9046=9.99, P=0.00163 | ||
| Median (interquartile range) | 30 (12—40) | 22 (6—36) | ||
| Range | 0—42 | 0—42 | ||
| Avg dose pre-delivery (mg) | 9048 (100.00) | F1,9046=1.06, P=0.30233 | ||
| Median (interquartile range) | 13.95 (8.00—16.00) | 12.62 (5.99—16.00) | ||
| Range | 0.00—50.00 | 0.00—50.00 | ||
| Avg dose post-delivery (mg) | 9048 (100.00) | F1,9046=0.10, P=0.75273 | ||
| Median (interquartile range) | 10.47 (4.00—16.00) | 10.21 (2.79—16.00) | ||
| Range | 0.00—380.00 | 0.00—31.00 | ||
| Avg dose exposure (mg) | 9048 (100.00) | F1,9046=0.00, P=0.95583 | ||
| Median (interquartile range) | 14.07 (9.59—16.00) | 13.71 (8.40—16.00) | ||
| Range | 0.00—380.00 | 1.94—50.00 | ||
| Total days buprenorphine before delivery (method 3) | 8816 (97.44) | F1,8814=6.92, P=0.00853 | ||
| Median (interquartile range) | 62.00 (30.00—77.83) | 49.00 (17.67—76.00) | ||
| Range | 0.00—90.00 | 0.00—89.00 | ||
| Total days buprenorphine after delivery (method 3) | 8816 (97.44) | F1,8814=13.54, P=0.00023 | ||
| Median (interquartile range) | 30.00 (12.00—40.00) | 22.00 (5.00—36.00) | ||
| Range | 0.00—42.00 | 0.00—42.00 | ||
| Total days supplied buprenorphine | 8816 (97.44) | F1,8814=11.99, P=0.00053 | ||
| Median (interquartile range) | 89.00 (45.00—112.00) | 71.00 (28.00—105.67) | ||
| Range | 1.00—132.00 | 2.00—131.00 | ||
| Avg dose BUP pre-delivery (mg) | 8816 (97.44) | F1,8814=2.18, P=0.13973 | ||
| Median (interquartile range) | 13.92 (8.00—16.00) | 12.44 (6.14—16.00) | ||
| Range | 0.00—40.00 | 0.00—24.24 | ||
| Avg dose BUP post-delivery (mg) | 8816 (97.44) | F1,8814=0.13, P=0.72263 | ||
| Median (interquartile range) | 9.88 (4.00—16.00) | 9.18 (0.00—16.00) | ||
| Range | 0.00—42.67 | 0.00—31.00 | ||
| Avg dose BUP exposure (mg) | 8816 (97.44) | F1,8814=0.00, P=0.97663 | ||
| Median (interquartile range) | 14.00 (9.21—16.00) | 13.36 (8.38—16.00) | ||
| Range | 0.00—42.67 | 1.00—31.00 | ||
| Combined pain : Yes | 9048 (100.00) | 7095/8900 (79.72) | 106/148 (71.62) |
Χ2 1=5.88, P=0.01542 |
| Schizophrenia or personality disorder : Yes | 9048 (100.00) | 655/8900 (7.36) | 21/148 (14.19) |
Χ2 1=9.82, P=0.00172 |
| Alcohol or other substance use : Yes | 9048 (100.00) | 3924/8900 (44.09) | 72/148 (48.65) |
Χ2 1=1.23, P=0.26802 |
| Benzodiazepine or anticonvulsant use : Yes | 9048 (100.00) | 1275/8900 (14.33) | 28/148 (18.92) |
Χ2 1=2.49, P=0.11452 |
| Maternal morbidity : Yes | 9048 (100.00) | 626/8900 (7.03) | 10/148 (6.76) |
Χ2 1=0.02, P=0.89602 |
| Anxiety and depression combined : Yes | 9048 (100.00) | 3991/8900 (44.84) | 94/148 (63.51) |
Χ2 1=20.49, P<0.00012 |
| Back pain : Yes | 9048 (100.00) | 3162/8900 (35.53) | 35/148 (23.65) |
Χ2 1=8.99, P=0.00272 |
| Med muscle relaxant use : Yes | 9048 (100.00) | 444/8900 (4.99) | 9/148 (6.08) |
Χ2 1=0.37, P=0.54562 |
| Med NSAIDS : Yes | 9048 (100.00) | 5650/8900 (63.48) | 87/148 (58.78) |
Χ2 1=1.39, P=0.23912 |
| Bipolar disorder : Yes | 9048 (100.00) | 883/8900 (9.92) | 31/148 (20.95) |
Χ2 1=19.48, P<0.00012 |
| Depression : Yes | 9048 (100.00) | 3402/8900 (38.22) | 87/148 (58.78) |
Χ2 1=25.97, P<0.00012 |
| Maternal morbidity : Yes | 9048 (100.00) | 626/8900 (7.03) | 10/148 (6.76) |
Χ2 1=0.02, P=0.89602 |
| Med benzodiazepine use : Yes | 9048 (100.00) | 875/8900 (9.83) | 15/148 (10.14) |
Χ2 1=0.02, P=0.90212 |
| Schizophrenia psychotic disorders : Yes | 9048 (100.00) | 523/8900 (5.88) | 19/148 (12.84) |
Χ2 1=12.53, P=0.00042 |
| Tobacco use : Yes | 9048 (100.00) | 6160/8900 (69.21) | 107/148 (72.30) |
Χ2 1=0.65, P=0.42002 |
| Dental pain : Yes | 9048 (100.00) | 341/8900 (3.83) | 7/148 (4.73) |
Χ2 1=0.32, P=0.57302 |
| Alcohol use disorder : Yes | 9048 (100.00) | 536/8900 (6.02) | 24/148 (16.22) |
Χ2 1=26.05, P<0.00012 |
| Other substance use : Yes | 9048 (100.00) | 3744/8900 (42.07) | 70/148 (47.30) |
Χ2 1=1.63, P=0.20132 |
| Anxiety : Yes | 9048 (100.00) | 1719/8900 (19.31) | 47/148 (31.76) |
Χ2 1=14.35, P=0.00022 |
| Fibromyalgia : Yes | 9048 (100.00) | 447/8900 (5.02) | 7/148 (4.73) |
Χ2 1=0.03, P=0.87152 |
| Med anticonvulsant use : Yes | 9048 (100.00) | 481/8900 (5.40) | 16/148 (10.81) |
Χ2 1=8.20, P=0.00422 |
| Personality disorder : Yes | 9048 (100.00) | 240/8900 (2.70) | 7/148 (4.73) |
Χ2 1=2.27, P=0.13222 |
| CDC SVI overall percentile ranking of all 4 themes | 8459 (93.49) | F1,8457=0.69, P=0.40693 | ||
| Median (interquartile range) | 0.58 (0.37—0.78) | 0.54 (0.33—0.81) | ||
| Range | 0.00—1.00 | 0.00—1.00 |
| N | All | |
|---|---|---|
| (N=9048) | ||
| MOUD pre-delivery (method 1) | 9048 (100.00) | |
| No MOUD | 823/9048 (9.10) | |
| MOUD | 8225/9048 (90.90) | |
| MOUD pre-delivery (method 2) | 9048 (100.00) | |
| No MOUD | 823/9048 (9.10) | |
| MOUD | 8225/9048 (90.90) | |
| MOUD pre-delivery (method 3) | 9048 (100.00) | |
| No MOUD | 830/9048 (9.17) | |
| MOUD | 8218/9048 (90.83) | |
| MOUD post-delivery (method 1) | 9048 (100.00) | |
| No MOUD | 1902/9048 (21.02) | |
| MOUD | 7146/9048 (78.98) | |
| MOUD post-delivery (method 2) | 9048 (100.00) | |
| No MOUD | 1033/9048 (11.42) | |
| MOUD | 8015/9048 (88.58) | |
| MOUD post-delivery (method 3) | 9048 (100.00) | |
| No MOUD | 1200/9048 (13.26) | |
| MOUD | 7848/9048 (86.74) | |
| MOUD pre and post (method 1) | 9048 (100.00) | |
| No MOUD | 0/9048 (0.00) | |
| Both pre and post | 6323/9048 (69.88) | |
| Either pre or post | 2725/9048 (30.12) | |
| MOUD pre and post (method 2) | 9048 (100.00) | |
| No MOUD | 0/9048 (0.00) | |
| Both pre and post | 7192/9048 (79.49) | |
| Either pre or post | 1856/9048 (20.51) | |
| MOUD pre and post (method 3) | 9048 (100.00) | |
| No MOUD | 0/9048 (0.00) | |
| Both pre and post | 7018/9048 (77.56) | |
| Either pre or post | 2030/9048 (22.44) |
| N | Both pre and post | Either pre or post | Test Statistic | |
|---|---|---|---|---|
| (N=7018) | (N=2030) | |||
| Year of delivery | 9048 (100.00) | F1,9046=7.23, P=0.00723 | ||
| Median (interquartile range) | 2016 (2014—2018) | 2016 (2014—2018) | ||
| Range | 2007—2020 | 2007—2020 | ||
| Year of delivery as categorical | 9048 (100.00) |
Χ2 13=58.99, P<0.00012 |
||
| 2007 | 36/7018 (0.51) | 15/2030 (0.74) | ||
| 2008 | 77/7018 (1.10) | 44/2030 (2.17) | ||
| 2009 | 130/7018 (1.85) | 46/2030 (2.27) | ||
| 2010 | 211/7018 (3.01) | 67/2030 (3.30) | ||
| 2011 | 250/7018 (3.56) | 73/2030 (3.60) | ||
| 2012 | 350/7018 (4.99) | 75/2030 (3.69) | ||
| 2013 | 568/7018 (8.09) | 125/2030 (6.16) | ||
| 2014 | 765/7018 (10.90) | 172/2030 (8.47) | ||
| 2015 | 940/7018 (13.39) | 233/2030 (11.48) | ||
| 2016 | 839/7018 (11.95) | 250/2030 (12.32) | ||
| 2017 | 687/7018 (9.79) | 245/2030 (12.07) | ||
| 2018 | 694/7018 (9.89) | 233/2030 (11.48) | ||
| 2019 | 703/7018 (10.02) | 234/2030 (11.53) | ||
| 2020 | 768/7018 (10.94) | 218/2030 (10.74) | ||
| Age at delivery | 9048 (100.00) | F1,9046=3.93, P=0.04733 | ||
| Median (interquartile range) | 27 (24—31) | 27 (24—30) | ||
| Range | 17—44 | 17—44 | ||
| Number of Gestation weeks | 9048 (100.00) | F1,9046=11.44, P=0.00073 | ||
| Median (interquartile range) | 39 (37—39) | 39 (37—39) | ||
| Range | 21—42 | 23—42 | ||
| Race | 9048 (100.00) |
Χ2 4=9.00, P=0.06102 |
||
| American Indian or Alaska Native | 14/7018 (0.20) | 7/2030 (0.34) | ||
| Asian or Pacific Islander | 10/7018 (0.14) | 2/2030 (0.10) | ||
| Black of African American | 172/7018 (2.45) | 70/2030 (3.45) | ||
| Other or Unknown | 43/7018 (0.61) | 17/2030 (0.84) | ||
| White | 6779/7018 (96.59) | 1934/2030 (95.27) | ||
| Hispanic : Not Hispanic | 9043 (99.94) | 6953/7016 (99.10) | 2011/2027 (99.21) |
Χ2 1=0.21, P=0.64352 |
| Race/Ethnicity combined | 9048 (100.00) |
Χ2 4=11.71, P=0.01962 |
||
| Hispanic | 63/7018 (0.90) | 16/2030 (0.79) | ||
| Non-Hispanic Asian | 9/7018 (0.13) | 2/2030 (0.10) | ||
| Non-Hispanic Black | 172/7018 (2.45) | 68/2030 (3.35) | ||
| Non-Hispanic Other | 37/7018 (0.53) | 21/2030 (1.03) | ||
| Non-Hispanic White | 6737/7018 (96.00) | 1923/2030 (94.73) | ||
| Route of delivery : Vaginal | 9048 (100.00) | 4509/7018 (64.25) | 1367/2030 (67.34) |
Χ2 1=6.61, P=0.01022 |
| Number of previous pregnancies | 8886 (98.21) | F1,8884=0.13, P=0.71453 | ||
| Median (interquartile range) | 2 (1—3) | 2 (1—3) | ||
| Range | 0—23 | 0—23 | ||
| Final outcome | 9048 (100.00) |
Χ2 3=23.77, P<0.00012 |
||
| Death | 30/7018 (0.43) | 9/2030 (0.44) | ||
| Overdose | 72/7018 (1.03) | 37/2030 (1.82) | ||
| Loss of enrollment | 745/7018 (10.62) | 277/2030 (13.65) | ||
| Censored | 6171/7018 (87.93) | 1707/2030 (84.09) | ||
| Final outcome 3 levels | 9048 (100.00) |
Χ2 2=8.41, P=0.01492 |
||
| Death | 30/7018 (0.43) | 9/2030 (0.44) | ||
| Overdose | 72/7018 (1.03) | 37/2030 (1.82) | ||
| Censored | 6916/7018 (98.55) | 1984/2030 (97.73) | ||
| Total days supplied MOUD | 9048 (100.00) | F1,9046=8769.92, P<0.00013 | ||
| Median (interquartile range) | 132 (104—132) | 42 (28—60) | ||
| Range | 4—132 | 1—98 | ||
| Total days supplied MOUD before delivery | 9048 (100.00) | F1,9046=5775.74, P<0.00013 | ||
| Median (interquartile range) | 90 (90—90) | 20 (0—60) | ||
| Range | 2—90 | 0—90 | ||
| Total days supplied MOUD after delivery | 9048 (100.00) | F1,9046=2656.27, P<0.00013 | ||
| Median (interquartile range) | 42 (33—42) | 0 (0—36) | ||
| Range | 0—42 | 0—42 | ||
| Total days supplied MOUD (method 2) | 9048 (100.00) | F1,9046=8414.06, P<0.00013 | ||
| Median (interquartile range) | 132 (132—132) | 42 (28—60) | ||
| Range | 4—132 | 1—132 | ||
| Total days supplied MOUD before delivery (method 2) | 9048 (100.00) | F1,9046=5775.74, P<0.00013 | ||
| Median (interquartile range) | 90 (90—90) | 20 (0—60) | ||
| Range | 2—90 | 0—90 | ||
| Total days supplied MOUD after delivery (method 2) | 9048 (100.00) | F1,9046=4335.52, P<0.00013 | ||
| Median (interquartile range) | 42 (42—42) | 14 (0—42) | ||
| Range | 0—42 | 0—42 | ||
| Total days supplied MOUD (method 3) | 9048 (100.00) | F1,9046=6982.53, P<0.00013 | ||
| Median (interquartile range) | 100 (76—116) | 22 (11—34) | ||
| Range | 2—132 | 1—89 | ||
| Total days supplied MOUD before delivery (method 3) | 9048 (100.00) | F1,9046=4304.76, P<0.00013 | ||
| Median (interquartile range) | 69 (48—80) | 10 (0—30) | ||
| Range | 1—90 | 0—89 | ||
| Total days supplied MOUD after delivery (method 3) | 9048 (100.00) | F1,9046=5668.64, P<0.00013 | ||
| Median (interquartile range) | 35 (23—41) | 0 (0—11) | ||
| Range | 1—42 | 0—41 | ||
| Avg dose pre-delivery (mg) | 9048 (100.00) | F1,9046=1112.53, P<0.00013 | ||
| Median (interquartile range) | 14.92 (9.79—16.00) | 6.00 (0.00—15.65) | ||
| Range | 0.25—50.00 | 0.00—50.00 | ||
| Avg dose post-delivery (mg) | 9048 (100.00) | F1,9046=1037.72, P<0.00013 | ||
| Median (interquartile range) | 12.00 (8.00—16.00) | 0.00 (0.00—13.57) | ||
| Range | 0.00—380.00 | 0.00—380.00 | ||
| Avg dose exposure (mg) | 9048 (100.00) | F1,9046=4.91, P=0.02683 | ||
| Median (interquartile range) | 14.04 (9.88—16.00) | 14.40 (8.00—16.00) | ||
| Range | 0.34—56.88 | 0.00—380.00 | ||
| Total days buprenorphine before delivery (method 3) | 8816 (97.44) | F1,8814=3812.74, P<0.00013 | ||
| Median (interquartile range) | 69.00 (48.00—80.00) | 13.00 (0.00—32.00) | ||
| Range | 0.00—90.00 | 0.00—89.00 | ||
| Total days buprenorphine after delivery (method 3) | 8816 (97.44) | F1,8814=5226.26, P<0.00013 | ||
| Median (interquartile range) | 35.00 (23.00—41.00) | 0.00 (0.00—9.00) | ||
| Range | 0.00—42.00 | 0.00—41.00 | ||
| Total days supplied buprenorphine | 8816 (97.44) | F1,8814=6204.54, P<0.00013 | ||
| Median (interquartile range) | 100.00 (76.00—116.00) | 22.00 (11.00—35.00) | ||
| Range | 2.00—132.00 | 1.00—89.00 | ||
| Avg dose BUP pre-delivery (mg) | 8816 (97.44) | F1,8814=981.32, P<0.00013 | ||
| Median (interquartile range) | 14.79 (9.54—16.00) | 7.60 (0.00—15.65) | ||
| Range | 0.00—40.00 | 0.00—32.00 | ||
| Avg dose BUP post-delivery (mg) | 8816 (97.44) | F1,8814=1152.98, P<0.00013 | ||
| Median (interquartile range) | 12.00 (8.00—16.00) | 0.00 (0.00—11.70) | ||
| Range | 0.00—33.24 | 0.00—42.67 | ||
| Avg dose BUP exposure (mg) | 8816 (97.44) | F1,8814=0.74, P=0.38903 | ||
| Median (interquartile range) | 13.96 (9.75—16.00) | 14.41 (8.00—16.00) | ||
| Range | 0.25—34.47 | 0.00—42.67 | ||
| Combined pain : Yes | 9048 (100.00) | 5607/7018 (79.89) | 1594/2030 (78.52) |
Χ2 1=1.83, P=0.17672 |
| Schizophrenia or personality disorder : Yes | 9048 (100.00) | 495/7018 (7.05) | 181/2030 (8.92) |
Χ2 1=7.90, P=0.00492 |
| Alcohol or other substance use : Yes | 9048 (100.00) | 3069/7018 (43.73) | 927/2030 (45.67) |
Χ2 1=2.39, P=0.12212 |
| Benzodiazepine or anticonvulsant use : Yes | 9048 (100.00) | 1031/7018 (14.69) | 272/2030 (13.40) |
Χ2 1=2.13, P=0.14432 |
| Maternal morbidity : Yes | 9048 (100.00) | 489/7018 (6.97) | 147/2030 (7.24) |
Χ2 1=0.18, P=0.67112 |
| Anxiety and depression combined : Yes | 9048 (100.00) | 3166/7018 (45.11) | 919/2030 (45.27) |
Χ2 1=0.02, P=0.89952 |
| Back pain : Yes | 9048 (100.00) | 2511/7018 (35.78) | 686/2030 (33.79) |
Χ2 1=2.72, P=0.09922 |
| Med muscle relaxant use : Yes | 9048 (100.00) | 316/7018 (4.50) | 137/2030 (6.75) |
Χ2 1=16.70, P<0.00012 |
| Med NSAIDS : Yes | 9048 (100.00) | 4463/7018 (63.59) | 1274/2030 (62.76) |
Χ2 1=0.47, P=0.49152 |
| Bipolar disorder : Yes | 9048 (100.00) | 711/7018 (10.13) | 203/2030 (10.00) |
Χ2 1=0.03, P=0.86302 |
| Depression : Yes | 9048 (100.00) | 2694/7018 (38.39) | 795/2030 (39.16) |
Χ2 1=0.40, P=0.52722 |
| Maternal morbidity : Yes | 9048 (100.00) | 489/7018 (6.97) | 147/2030 (7.24) |
Χ2 1=0.18, P=0.67112 |
| Med benzodiazepine use : Yes | 9048 (100.00) | 695/7018 (9.90) | 195/2030 (9.61) |
Χ2 1=0.16, P=0.69212 |
| Schizophrenia psychotic disorders : Yes | 9048 (100.00) | 400/7018 (5.70) | 142/2030 (7.00) |
Χ2 1=4.69, P=0.03032 |
| Tobacco use : Yes | 9048 (100.00) | 4862/7018 (69.28) | 1405/2030 (69.21) |
Χ2 1=0.00, P=0.95392 |
| Dental pain : Yes | 9048 (100.00) | 255/7018 (3.63) | 93/2030 (4.58) |
Χ2 1=3.82, P=0.05052 |
| Alcohol use disorder : Yes | 9048 (100.00) | 416/7018 (5.93) | 144/2030 (7.09) |
Χ2 1=3.69, P=0.05482 |
| Other substance use : Yes | 9048 (100.00) | 2916/7018 (41.55) | 898/2030 (44.24) |
Χ2 1=4.66, P=0.03092 |
| Anxiety : Yes | 9048 (100.00) | 1363/7018 (19.42) | 403/2030 (19.85) |
Χ2 1=0.19, P=0.66632 |
| Fibromyalgia : Yes | 9048 (100.00) | 349/7018 (4.97) | 105/2030 (5.17) |
Χ2 1=0.13, P=0.71692 |
| Med anticonvulsant use : Yes | 9048 (100.00) | 403/7018 (5.74) | 94/2030 (4.63) |
Χ2 1=3.75, P=0.05282 |
| Personality disorder : Yes | 9048 (100.00) | 174/7018 (2.48) | 73/2030 (3.60) |
Χ2 1=7.39, P=0.00652 |
| CDC SVI overall percentile ranking of all 4 themes | 8459 (93.49) | F1,8457=3.13, P=0.07673 | ||
| Median (interquartile range) | 0.57 (0.37—0.78) | 0.59 (0.38—0.79) | ||
| Range | 0.00—1.00 | 0.00—1.00 |
| N | Only pre | Only post | Both pre and post | Test Statistic | |
|---|---|---|---|---|---|
| (N=1200) | (N=830) | (N=7018) | |||
| Year of delivery | 9048 (100.00) | F2,9045=10.35, P<0.00011 | |||
| Median (interquartile range) | 2016 (2014—2018) | 2016 (2013—2019) | 2016 (2014—2018) | ||
| Range | 2007—2020 | 2007—2020 | 2007—2020 | ||
| Year of delivery as categorical | 9048 (100.00) |
Χ2 26=217.18, P<0.00012 |
|||
| 2007 | 3/1200 (0.25) | 12/830 (1.45) | 36/7018 (0.51) | ||
| 2008 | 10/1200 (0.83) | 34/830 (4.10) | 77/7018 (1.10) | ||
| 2009 | 16/1200 (1.33) | 30/830 (3.61) | 130/7018 (1.85) | ||
| 2010 | 19/1200 (1.58) | 48/830 (5.78) | 211/7018 (3.01) | ||
| 2011 | 38/1200 (3.17) | 35/830 (4.22) | 250/7018 (3.56) | ||
| 2012 | 46/1200 (3.83) | 29/830 (3.49) | 350/7018 (4.99) | ||
| 2013 | 67/1200 (5.58) | 58/830 (6.99) | 568/7018 (8.09) | ||
| 2014 | 103/1200 (8.58) | 69/830 (8.31) | 765/7018 (10.90) | ||
| 2015 | 154/1200 (12.83) | 79/830 (9.52) | 940/7018 (13.39) | ||
| 2016 | 179/1200 (14.92) | 71/830 (8.55) | 839/7018 (11.95) | ||
| 2017 | 160/1200 (13.33) | 85/830 (10.24) | 687/7018 (9.79) | ||
| 2018 | 172/1200 (14.33) | 61/830 (7.35) | 694/7018 (9.89) | ||
| 2019 | 130/1200 (10.83) | 104/830 (12.53) | 703/7018 (10.02) | ||
| 2020 | 103/1200 (8.58) | 115/830 (13.86) | 768/7018 (10.94) | ||
| Age at delivery | 9048 (100.00) | F2,9045=2.32, P=0.09791 | |||
| Median (interquartile range) | 27 (24—30) | 27 (24—31) | 27 (24—31) | ||
| Range | 17—43 | 17—44 | 17—44 | ||
| Number of Gestation weeks | 9048 (100.00) | F2,9045=8.79, P=0.00021 | |||
| Median (interquartile range) | 39 (37—39) | 38 (37—39) | 39 (37—39) | ||
| Range | 24—42 | 23—42 | 21—42 | ||
| Race | 9048 (100.00) |
Χ2 8=10.46, P=0.23392 |
|||
| American Indian or Alaska Native | 4/1200 (0.33) | 3/830 (0.36) | 14/7018 (0.20) | ||
| Asian or Pacific Islander | 1/1200 (0.08) | 1/830 (0.12) | 10/7018 (0.14) | ||
| Black of African American | 43/1200 (3.58) | 27/830 (3.25) | 172/7018 (2.45) | ||
| Other or Unknown | 12/1200 (1.00) | 5/830 (0.60) | 43/7018 (0.61) | ||
| White | 1140/1200 (95.00) | 794/830 (95.66) | 6779/7018 (96.59) | ||
| Hispanic : Not Hispanic | 9043 (99.94) | 1188/1198 (99.17) | 823/829 (99.28) | 6953/7016 (99.10) |
Χ2 2=0.28, P=0.86772 |
| Race/Ethnicity combined | 9048 (100.00) |
Χ2 8=12.92, P=0.11482 |
|||
| Hispanic | 10/1200 (0.83) | 6/830 (0.72) | 63/7018 (0.90) | ||
| Non-Hispanic Asian | 1/1200 (0.08) | 1/830 (0.12) | 9/7018 (0.13) | ||
| Non-Hispanic Black | 42/1200 (3.50) | 26/830 (3.13) | 172/7018 (2.45) | ||
| Non-Hispanic Other | 14/1200 (1.17) | 7/830 (0.84) | 37/7018 (0.53) | ||
| Non-Hispanic White | 1133/1200 (94.42) | 790/830 (95.18) | 6737/7018 (96.00) | ||
| Route of delivery : Vaginal | 9048 (100.00) | 817/1200 (68.08) | 550/830 (66.27) | 4509/7018 (64.25) |
Χ2 2=7.32, P=0.02572 |
| Number of previous pregnancies | 8886 (98.21) | F2,8883=0.09, P=0.91211 | |||
| Median (interquartile range) | 2 (1—3) | 2 (1—3) | 2 (1—3) | ||
| Range | 0—19 | 0—23 | 0—23 | ||
| Final outcome | 9048 (100.00) |
Χ2 6=31.07, P<0.00012 |
|||
| Death | 3/1200 (0.25) | 6/830 (0.72) | 30/7018 (0.43) | ||
| Overdose | 20/1200 (1.67) | 17/830 (2.05) | 72/7018 (1.03) | ||
| Loss of enrollment | 150/1200 (12.50) | 127/830 (15.30) | 745/7018 (10.62) | ||
| Censored | 1027/1200 (85.58) | 680/830 (81.93) | 6171/7018 (87.93) | ||
| Final outcome 3 levels | 9048 (100.00) |
Χ2 4=11.59, P=0.02072 |
|||
| Death | 3/1200 (0.25) | 6/830 (0.72) | 30/7018 (0.43) | ||
| Overdose | 20/1200 (1.67) | 17/830 (2.05) | 72/7018 (1.03) | ||
| Censored | 1177/1200 (98.08) | 807/830 (97.23) | 6916/7018 (98.55) | ||
| Total days supplied MOUD | 9048 (100.00) | F2,9045=4479.01, P<0.00011 | |||
| Median (interquartile range) | 60 (28—90) | 42 (28—42) | 132 (104—132) | ||
| Range | 2—90 | 1—98 | 4—132 | ||
| Total days supplied MOUD before delivery | 9048 (100.00) | F2,9045=3895.76, P<0.00011 | |||
| Median (interquartile range) | 60 (28—90) | 0 (0—0) | 90 (90—90) | ||
| Range | 2—90 | 0—56 | 2—90 | ||
| Total days supplied MOUD after delivery | 9048 (100.00) | F2,9045=2717.41, P<0.00011 | |||
| Median (interquartile range) | 0 (0—0) | 42 (28—42) | 42 (33—42) | ||
| Range | 0—0 | 1—42 | 0—42 | ||
| Total days supplied MOUD (method 2) | 9048 (100.00) | F2,9045=4453.24, P<0.00011 | |||
| Median (interquartile range) | 60 (28—99) | 42 (28—42) | 132 (132—132) | ||
| Range | 2—132 | 1—98 | 4—132 | ||
| Total days supplied MOUD before delivery (method 2) | 9048 (100.00) | F2,9045=3895.76, P<0.00011 | |||
| Median (interquartile range) | 60 (28—90) | 0 (0—0) | 90 (90—90) | ||
| Range | 2—90 | 0—56 | 2—90 | ||
| Total days supplied MOUD after delivery (method 2) | 9048 (100.00) | F2,9045=3276.43, P<0.00011 | |||
| Median (interquartile range) | 0 (0—9) | 42 (28—42) | 42 (42—42) | ||
| Range | 0—42 | 1—42 | 0—42 | ||
| Total days supplied MOUD (method 3) | 9048 (100.00) | F2,9045=3571.31, P<0.00011 | |||
| Median (interquartile range) | 30 (14—47) | 14 (7—24) | 100 (76—116) | ||
| Range | 1—89 | 1—41 | 2—132 | ||
| Total days supplied MOUD before delivery (method 3) | 9048 (100.00) | F2,9045=2589.45, P<0.00011 | |||
| Median (interquartile range) | 30 (14—47) | 0 (0—0) | 69 (48—80) | ||
| Range | 1—89 | 0—0 | 1—90 | ||
| Total days supplied MOUD after delivery (method 3) | 9048 (100.00) | F2,9045=3359.62, P<0.00011 | |||
| Median (interquartile range) | 0 (0—0) | 14 (7—24) | 35 (23—41) | ||
| Range | 0—0 | 1—41 | 1—42 | ||
| Avg dose pre-delivery (mg) | 9048 (100.00) | F2,9045=1574.23, P<0.00011 | |||
| Median (interquartile range) | 14.00 (8.00—16.00) | 0.00 (0.00—0.00) | 14.92 (9.79—16.00) | ||
| Range | 0.00—50.00 | 0.00—0.00 | 0.25—50.00 | ||
| Avg dose post-delivery (mg) | 9048 (100.00) | F2,9045=1993.04, P<0.00011 | |||
| Median (interquartile range) | 0.00 (0.00—0.00) | 15.32 (9.33—16.00) | 12.00 (8.00—16.00) | ||
| Range | 0.00—0.00 | 0.00—380.00 | 0.00—380.00 | ||
| Avg dose exposure (mg) | 9048 (100.00) | F2,9045=15.65, P<0.00011 | |||
| Median (interquartile range) | 14.00 (8.00—16.00) | 15.32 (9.33—16.00) | 14.04 (9.88—16.00) | ||
| Range | 0.00—50.00 | 0.00—380.00 | 0.34—56.88 | ||
| Total days buprenorphine before delivery (method 3) | 8816 (97.44) | F2,8813=2259.60, P<0.00011 | |||
| Median (interquartile range) | 30.00 (14.00—47.00) | 0.00 (0.00—0.00) | 69.00 (48.00—80.00) | ||
| Range | 1.00—89.00 | 0.00—0.00 | 0.00—90.00 | ||
| Total days buprenorphine after delivery (method 3) | 8816 (97.44) | F2,8813=3058.36, P<0.00011 | |||
| Median (interquartile range) | 0.00 (0.00—0.00) | 14.00 (7.00—24.83) | 35.00 (23.00—41.00) | ||
| Range | 0.00—0.00 | 1.00—41.00 | 0.00—42.00 | ||
| Total days supplied buprenorphine | 8816 (97.44) | F2,8813=3162.34, P<0.00011 | |||
| Median (interquartile range) | 30.00 (14.00—47.00) | 14.00 (7.00—24.83) | 100.00 (76.00—116.00) | ||
| Range | 1.00—89.00 | 1.00—41.00 | 2.00—132.00 | ||
| Avg dose BUP pre-delivery (mg) | 8816 (97.44) | F2,8813=1327.50, P<0.00011 | |||
| Median (interquartile range) | 13.45 (8.00—16.00) | 0.00 (0.00—0.00) | 14.79 (9.54—16.00) | ||
| Range | 0.00—32.00 | 0.00—0.00 | 0.00—40.00 | ||
| Avg dose BUP post-delivery (mg) | 8816 (97.44) | F2,8813=1877.30, P<0.00011 | |||
| Median (interquartile range) | 0.00 (0.00—0.00) | 16.00 (8.40—16.00) | 12.00 (8.00—16.00) | ||
| Range | 0.00—0.00 | 0.00—42.67 | 0.00—33.24 | ||
| Avg dose BUP exposure (mg) | 8816 (97.44) | F2,8813=15.89, P<0.00011 | |||
| Median (interquartile range) | 13.45 (8.00—16.00) | 16.00 (8.40—16.00) | 13.96 (9.75—16.00) | ||
| Range | 0.00—32.00 | 0.00—42.67 | 0.25—34.47 | ||
| Combined pain : Yes | 9048 (100.00) | 947/1200 (78.92) | 647/830 (77.95) | 5607/7018 (79.89) |
Χ2 2=2.11, P=0.34882 |
| Schizophrenia or personality disorder : Yes | 9048 (100.00) | 98/1200 (8.17) | 83/830 (10.00) | 495/7018 (7.05) |
Χ2 2=10.29, P=0.00582 |
| Alcohol or other substance use : Yes | 9048 (100.00) | 547/1200 (45.58) | 380/830 (45.78) | 3069/7018 (43.73) |
Χ2 2=2.40, P=0.30152 |
| Benzodiazepine or anticonvulsant use : Yes | 9048 (100.00) | 160/1200 (13.33) | 112/830 (13.49) | 1031/7018 (14.69) |
Χ2 2=2.14, P=0.34272 |
| Maternal morbidity : Yes | 9048 (100.00) | 87/1200 (7.25) | 60/830 (7.23) | 489/7018 (6.97) |
Χ2 2=0.18, P=0.91362 |
| Anxiety and depression combined : Yes | 9048 (100.00) | 509/1200 (42.42) | 410/830 (49.40) | 3166/7018 (45.11) |
Χ2 2=9.67, P=0.00792 |
| Back pain : Yes | 9048 (100.00) | 415/1200 (34.58) | 271/830 (32.65) | 2511/7018 (35.78) |
Χ2 2=3.52, P=0.17202 |
| Med muscle relaxant use : Yes | 9048 (100.00) | 71/1200 (5.92) | 66/830 (7.95) | 316/7018 (4.50) |
Χ2 2=20.97, P<0.00012 |
| Med NSAIDS : Yes | 9048 (100.00) | 750/1200 (62.50) | 524/830 (63.13) | 4463/7018 (63.59) |
Χ2 2=0.56, P=0.75662 |
| Bipolar disorder : Yes | 9048 (100.00) | 132/1200 (11.00) | 71/830 (8.55) | 711/7018 (10.13) |
Χ2 2=3.26, P=0.19582 |
| Depression : Yes | 9048 (100.00) | 430/1200 (35.83) | 365/830 (43.98) | 2694/7018 (38.39) |
Χ2 2=14.13, P=0.00092 |
| Maternal morbidity : Yes | 9048 (100.00) | 87/1200 (7.25) | 60/830 (7.23) | 489/7018 (6.97) |
Χ2 2=0.18, P=0.91362 |
| Med benzodiazepine use : Yes | 9048 (100.00) | 117/1200 (9.75) | 78/830 (9.40) | 695/7018 (9.90) |
Χ2 2=0.23, P=0.89342 |
| Schizophrenia psychotic disorders : Yes | 9048 (100.00) | 78/1200 (6.50) | 64/830 (7.71) | 400/7018 (5.70) |
Χ2 2=5.97, P=0.05062 |
| Tobacco use : Yes | 9048 (100.00) | 862/1200 (71.83) | 543/830 (65.42) | 4862/7018 (69.28) |
Χ2 2=9.48, P=0.00872 |
| Dental pain : Yes | 9048 (100.00) | 55/1200 (4.58) | 38/830 (4.58) | 255/7018 (3.63) |
Χ2 2=3.82, P=0.14782 |
| Alcohol use disorder : Yes | 9048 (100.00) | 74/1200 (6.17) | 70/830 (8.43) | 416/7018 (5.93) |
Χ2 2=8.03, P=0.01802 |
| Other substance use : Yes | 9048 (100.00) | 535/1200 (44.58) | 363/830 (43.73) | 2916/7018 (41.55) |
Χ2 2=4.80, P=0.09052 |
| Anxiety : Yes | 9048 (100.00) | 245/1200 (20.42) | 158/830 (19.04) | 1363/7018 (19.42) |
Χ2 2=0.78, P=0.67662 |
| Fibromyalgia : Yes | 9048 (100.00) | 63/1200 (5.25) | 42/830 (5.06) | 349/7018 (4.97) |
Χ2 2=0.17, P=0.91922 |
| Med anticonvulsant use : Yes | 9048 (100.00) | 55/1200 (4.58) | 39/830 (4.70) | 403/7018 (5.74) |
Χ2 2=3.76, P=0.15242 |
| Personality disorder : Yes | 9048 (100.00) | 38/1200 (3.17) | 35/830 (4.22) | 174/7018 (2.48) |
Χ2 2=9.43, P=0.00892 |
| CDC SVI overall percentile ranking of all 4 themes | 8459 (93.49) | F2,8456=5.74, P=0.00321 | |||
| Median (interquartile range) | 0.62 (0.40—0.81) | 0.57 (0.36—0.75) | 0.57 (0.37—0.78) | ||
| Range | 0.00—1.00 | 0.00—1.00 | 0.00—1.00 |
Call: survfit(formula = Surv(days.to.event, outcome.bin) ~ 1, data = moud)
n events median 0.95LCL 0.95UCL
[1,] 9048 148 NA NA NA
Min. 1st Qu. Median Mean 3rd Qu. Max.
2.0 92.5 184.5 176.2 258.8 323.0
| time | probability |
|---|---|
| 2 | 0.9998895 |
| 7 | 0.9997790 |
| 8 | 0.9995579 |
| 10 | 0.9994474 |
| 17 | 0.9993369 |
| 18 | 0.9992263 |
| 19 | 0.9991158 |
| 27 | 0.9990053 |
| 32 | 0.9988948 |
| 34 | 0.9987843 |
| 35 | 0.9985632 |
| 38 | 0.9984527 |
| 41 | 0.9983422 |
| 42 | 0.9982317 |
| 43 | 0.9981211 |
| 45 | 0.9979001 |
| 47 | 0.9977896 |
| 52 | 0.9975685 |
| 59 | 0.9973475 |
| 60 | 0.9972370 |
| 61 | 0.9971264 |
| 63 | 0.9970159 |
| 65 | 0.9969054 |
| 66 | 0.9967949 |
| 69 | 0.9966844 |
| 70 | 0.9965738 |
| 72 | 0.9964633 |
| 75 | 0.9963528 |
| 77 | 0.9962423 |
| 87 | 0.9961317 |
| 91 | 0.9960212 |
| 93 | 0.9959107 |
| 95 | 0.9958002 |
| 97 | 0.9956897 |
| 101 | 0.9954686 |
| 110 | 0.9953581 |
| 111 | 0.9952476 |
| 112 | 0.9951370 |
| 118 | 0.9949160 |
| 120 | 0.9948055 |
| 121 | 0.9946950 |
| 125 | 0.9945844 |
| 128 | 0.9944739 |
| 131 | 0.9943634 |
| 138 | 0.9941424 |
| 140 | 0.9940318 |
| 144 | 0.9939213 |
| 147 | 0.9938108 |
| 151 | 0.9935897 |
| 153 | 0.9934792 |
| 156 | 0.9932582 |
| 166 | 0.9931477 |
| 169 | 0.9930371 |
| 171 | 0.9929266 |
| 173 | 0.9928161 |
| 175 | 0.9927056 |
| 177 | 0.9925950 |
| 178 | 0.9924845 |
| 180 | 0.9923740 |
| 181 | 0.9922635 |
| 182 | 0.9921530 |
| 184 | 0.9920424 |
| 185 | 0.9919319 |
| 188 | 0.9917109 |
| 193 | 0.9916004 |
| 199 | 0.9914898 |
| 204 | 0.9913793 |
| 208 | 0.9912688 |
| 211 | 0.9911583 |
| 213 | 0.9909372 |
| 214 | 0.9908267 |
| 215 | 0.9906057 |
| 216 | 0.9904951 |
| 217 | 0.9902741 |
| 220 | 0.9901636 |
| 222 | 0.9900531 |
| 223 | 0.9899425 |
| 228 | 0.9897215 |
| 229 | 0.9896110 |
| 233 | 0.9895004 |
| 235 | 0.9893899 |
| 236 | 0.9892794 |
| 239 | 0.9891689 |
| 240 | 0.9889478 |
| 242 | 0.9888373 |
| 244 | 0.9887268 |
| 245 | 0.9886163 |
| 246 | 0.9883952 |
| 247 | 0.9882847 |
| 250 | 0.9881742 |
| 253 | 0.9880637 |
| 254 | 0.9879531 |
| 258 | 0.9878426 |
| 261 | 0.9876216 |
| 262 | 0.9875111 |
| 263 | 0.9874005 |
| 265 | 0.9872900 |
| 267 | 0.9871795 |
| 268 | 0.9870690 |
| 270 | 0.9868479 |
| 271 | 0.9867374 |
| 272 | 0.9866269 |
| 274 | 0.9864058 |
| 275 | 0.9862953 |
| 279 | 0.9861848 |
| 281 | 0.9860743 |
| 287 | 0.9858532 |
| 289 | 0.9857427 |
| 290 | 0.9856322 |
| 295 | 0.9854111 |
| 296 | 0.9853006 |
| 298 | 0.9850796 |
| 300 | 0.9849691 |
| 301 | 0.9848585 |
| 302 | 0.9847480 |
| 304 | 0.9846375 |
| 305 | 0.9845270 |
| 308 | 0.9843059 |
| 310 | 0.9840849 |
| 313 | 0.9839744 |
| 316 | 0.9838638 |
| 319 | 0.9837533 |
| 321 | 0.9836428 |
| 323 | 0.9836428 |
| n | missing | distinct | Info | Mean | pMedian | Gmd | .05 | .10 | .25 | .50 | .75 | .90 | .95 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 148 | 0 | 123 | 1 | 177.3 | 177.5 | 108.5 | 21.8 | 41.7 | 94.5 | 188.0 | 261.0 | 296.6 | 307.0 |
| n | missing | distinct | Info | Mean | pMedian | Gmd | .05 | .10 | .25 | .50 | .75 | .90 | .95 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 39 | 0 | 38 | 1 | 156.7 | 156.5 | 112.7 | 18.8 | 34.4 | 60.0 | 171.0 | 243.5 | 279.4 | 290.5 |
| n | missing | distinct | Info | Mean | pMedian | Gmd | .05 | .10 | .25 | .50 | .75 | .90 | .95 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 109 | 0 | 98 | 1 | 184.7 | 185.5 | 106.5 | 29.8 | 44.6 | 111.0 | 208.0 | 262.0 | 300.2 | 309.2 |
Effects Response: Surv(days.to.event, outcome.bin) | |||||||
| Low | High | Δ | Effect | S.E. | Lower 0.95 | Upper 0.95 | |
|---|---|---|---|---|---|---|---|
| Year of delivery | 2016 | 2018 | 2 | 0.34850 | 0.08003 | 0.191600 | 0.50540 |
| Hazard Ratio | 2016 | 2018 | 2 | 1.41700 | 1.211000 | 1.65800 | |
| Total days supplied MOUD (method 3) | 1 | 31 | 30 | -0.16070 | 0.06072 | -0.279700 | -0.04172 |
| Hazard Ratio | 1 | 31 | 30 | 0.85150 | 0.756000 | 0.95910 | |
| Age at delivery | 27 | 31 | 4 | -0.05909 | 0.07189 | -0.200000 | 0.08181 |
| Hazard Ratio | 27 | 31 | 4 | 0.94260 | 0.818700 | 1.08500 | |
| Number of Gestation weeks | 39 | 37 | -2 | 0.12530 | 0.06235 | 0.003128 | 0.24750 |
| Hazard Ratio | 39 | 37 | -2 | 1.13400 | 1.003000 | 1.28100 | |
| Route of delivery --- Cesarean:Vaginal | 2 | 1 | -0.01527 | 0.17740 | -0.362900 | 0.33240 | |
| Hazard Ratio | 2 | 1 | 0.98480 | 0.695600 | 1.39400 | ||
| Combined pain --- Yes:No | 1 | 2 | -0.26220 | 0.18590 | -0.626600 | 0.10230 | |
| Hazard Ratio | 1 | 2 | 0.76940 | 0.534400 | 1.10800 | ||
| Alcohol or other substance use --- Yes:No | 1 | 2 | 0.18920 | 0.17040 | -0.144800 | 0.52330 | |
| Hazard Ratio | 1 | 2 | 1.20800 | 0.865200 | 1.68800 | ||
| Benzodiazepine or anticonvulsant use --- Yes:No | 1 | 2 | 0.29500 | 0.21210 | -0.120700 | 0.71070 | |
| Hazard Ratio | 1 | 2 | 1.34300 | 0.886300 | 2.03500 | ||
| Anxiety and depression combined --- Yes:No | 1 | 2 | 0.53420 | 0.18040 | 0.180700 | 0.88770 | |
| Hazard Ratio | 1 | 2 | 1.70600 | 1.198000 | 2.43000 | ||
| Maternal morbidity --- Yes:No | 1 | 2 | -0.03872 | 0.35230 | -0.729200 | 0.65180 | |
| Hazard Ratio | 1 | 2 | 0.96200 | 0.482300 | 1.91900 | ||
Wald Statistics for Surv(days.to.event, outcome.bin) | |||
| χ2 | d.f. | P | |
|---|---|---|---|
| Year of delivery | 18.93 | 1 | <0.0001 |
| Total days supplied MOUD (method 3) | 7.01 | 1 | 0.0081 |
| Age at delivery | 0.68 | 1 | 0.4107 |
| Route of delivery | 0.01 | 1 | 0.9314 |
| Number of Gestation weeks | 4.05 | 1 | 0.0443 |
| Combined pain | 1.99 | 1 | 0.1585 |
| Alcohol or other substance use | 1.23 | 1 | 0.2668 |
| Benzodiazepine or anticonvulsant use | 1.94 | 1 | 0.1639 |
| Anxiety and depression combined | 8.76 | 1 | 0.0031 |
| Maternal morbidity | 0.01 | 1 | 0.9124 |
| TOTAL | 65.24 | 10 | <0.0001 |
Effects Response: Surv(days.to.event, outcome.bin) | |||||||
| Low | High | Δ | Effect | S.E. | Lower 0.95 | Upper 0.95 | |
|---|---|---|---|---|---|---|---|
| Total days supplied MOUD (method 3) | 1 | 31 | 30 | -0.1901 | 0.06122 | -0.3101 | -0.07009 |
| Hazard Ratio | 1 | 31 | 30 | 0.8269 | 0.7334 | 0.93230 | |
Wald Statistics for Surv(days.to.event, outcome.bin) | |||
| χ2 | d.f. | P | |
|---|---|---|---|
| Total days supplied MOUD (method 3) | 9.63 | 1 | 0.0019 |
| TOTAL | 9.63 | 1 | 0.0019 |
Effects Response: Surv(days.to.event, outcome.bin) | |||||||
| Low | High | Δ | Effect | S.E. | Lower 0.95 | Upper 0.95 | |
|---|---|---|---|---|---|---|---|
| Year of delivery | 2016 | 2018 | 2 | 0.42100 | 0.09150 | 0.2417000 | 0.60040 |
| Hazard Ratio | 2016 | 2018 | 2 | 1.52400 | 1.2730000 | 1.82300 | |
| Total days supplied MOUD (method 3) | 1 | 31 | 30 | -0.16190 | 0.06017 | -0.2798000 | -0.04399 |
| Hazard Ratio | 1 | 31 | 30 | 0.85050 | 0.7559000 | 0.95700 | |
| Age at delivery | 27 | 31 | 4 | -0.06195 | 0.07171 | -0.2025000 | 0.07860 |
| Hazard Ratio | 27 | 31 | 4 | 0.93990 | 0.8167000 | 1.08200 | |
| Number of Gestation weeks | 39 | 37 | -2 | 0.12370 | 0.06282 | 0.0005376 | 0.24680 |
| Hazard Ratio | 39 | 37 | -2 | 1.13200 | 1.0010000 | 1.28000 | |
| Route of delivery --- Cesarean:Vaginal | 2 | 1 | -0.01485 | 0.17730 | -0.3624000 | 0.33270 | |
| Hazard Ratio | 2 | 1 | 0.98530 | 0.6960000 | 1.39500 | ||
| Combined pain --- Yes:No | 1 | 2 | -0.27250 | 0.18690 | -0.6389000 | 0.09388 | |
| Hazard Ratio | 1 | 2 | 0.76150 | 0.5279000 | 1.09800 | ||
| Alcohol or other substance use --- Yes:No | 1 | 2 | 0.19770 | 0.17150 | -0.1384000 | 0.53380 | |
| Hazard Ratio | 1 | 2 | 1.21900 | 0.8707000 | 1.70500 | ||
| Benzodiazepine or anticonvulsant use --- Yes:No | 1 | 2 | 0.31260 | 0.21520 | -0.1091000 | 0.73430 | |
| Hazard Ratio | 1 | 2 | 1.36700 | 0.8966000 | 2.08400 | ||
| Anxiety and depression combined --- Yes:No | 1 | 2 | 0.53080 | 0.18050 | 0.1770000 | 0.88460 | |
| Hazard Ratio | 1 | 2 | 1.70000 | 1.1940000 | 2.42200 | ||
| Maternal morbidity --- Yes:No | 1 | 2 | -0.04133 | 0.35150 | -0.7302000 | 0.64750 | |
| Hazard Ratio | 1 | 2 | 0.95950 | 0.4818000 | 1.91100 | ||
Wald Statistics for Surv(days.to.event, outcome.bin) | |||
| χ2 | d.f. | P | |
|---|---|---|---|
| Year of delivery | 26.47 | 2 | <0.0001 |
| Nonlinear | 1.44 | 1 | 0.2308 |
| Total days supplied MOUD (method 3) | 7.24 | 1 | 0.0071 |
| Age at delivery | 0.75 | 1 | 0.3872 |
| Route of delivery | 0.01 | 1 | 0.9333 |
| Number of Gestation weeks | 3.88 | 1 | 0.0488 |
| Combined pain | 2.13 | 1 | 0.1449 |
| Alcohol or other substance use | 1.33 | 1 | 0.2489 |
| Benzodiazepine or anticonvulsant use | 2.11 | 1 | 0.1459 |
| Anxiety and depression combined | 8.64 | 1 | 0.0033 |
| Maternal morbidity | 0.01 | 1 | 0.9063 |
| TOTAL | 75.63 | 11 | <0.0001 |
Effects Response: Surv(days.to.event, outcome.bin) | |||||||
| Low | High | Δ | Effect | S.E. | Lower 0.95 | Upper 0.95 | |
|---|---|---|---|---|---|---|---|
| Year of delivery | 2016 | 2018 | 2 | 0.36370 | 0.08187 | 0.20320 | 0.52410 |
| Hazard Ratio | 2016 | 2018 | 2 | 1.43900 | 1.22500 | 1.68900 | |
| Total days supplied buprenorphine | 1 | 31 | 30 | -0.19710 | 0.06216 | -0.31890 | -0.07527 |
| Hazard Ratio | 1 | 31 | 30 | 0.82110 | 0.72690 | 0.92750 | |
| Age at delivery | 27 | 31 | 4 | -0.05378 | 0.07267 | -0.19620 | 0.08865 |
| Hazard Ratio | 27 | 31 | 4 | 0.94760 | 0.82180 | 1.09300 | |
| Number of Gestation weeks | 39 | 37 | -2 | 0.13170 | 0.06160 | 0.01096 | 0.25240 |
| Hazard Ratio | 39 | 37 | -2 | 1.14100 | 1.01100 | 1.28700 | |
| Route of delivery --- Cesarean:Vaginal | 2 | 1 | -0.07969 | 0.18050 | -0.43340 | 0.27400 | |
| Hazard Ratio | 2 | 1 | 0.92340 | 0.64830 | 1.31500 | ||
| Combined pain --- Yes:No | 1 | 2 | -0.26570 | 0.18690 | -0.63200 | 0.10060 | |
| Hazard Ratio | 1 | 2 | 0.76670 | 0.53150 | 1.10600 | ||
| Alcohol or other substance use --- Yes:No | 1 | 2 | 0.25720 | 0.17210 | -0.08015 | 0.59460 | |
| Hazard Ratio | 1 | 2 | 1.29300 | 0.92300 | 1.81200 | ||
| Benzodiazepine or anticonvulsant use --- Yes:No | 1 | 2 | 0.30620 | 0.21270 | -0.11070 | 0.72310 | |
| Hazard Ratio | 1 | 2 | 1.35800 | 0.89520 | 2.06100 | ||
| Anxiety and depression combined --- Yes:No | 1 | 2 | 0.53630 | 0.18100 | 0.18160 | 0.89110 | |
| Hazard Ratio | 1 | 2 | 1.71000 | 1.19900 | 2.43800 | ||
| Maternal morbidity --- Yes:No | 1 | 2 | -0.03741 | 0.35310 | -0.72950 | 0.65470 | |
| Hazard Ratio | 1 | 2 | 0.96330 | 0.48220 | 1.92400 | ||
Wald Statistics for Surv(days.to.event, outcome.bin) | |||
| χ2 | d.f. | P | |
|---|---|---|---|
| Year of delivery | 19.70 | 1 | <0.0001 |
| Total days supplied buprenorphine | 10.05 | 1 | 0.0015 |
| Age at delivery | 0.55 | 1 | 0.4589 |
| Route of delivery | 0.19 | 1 | 0.6590 |
| Number of Gestation weeks | 4.58 | 1 | 0.0324 |
| Combined pain | 2.02 | 1 | 0.1552 |
| Alcohol or other substance use | 2.23 | 1 | 0.1349 |
| Benzodiazepine or anticonvulsant use | 2.08 | 1 | 0.1497 |
| Anxiety and depression combined | 8.77 | 1 | 0.0031 |
| Maternal morbidity | 0.01 | 1 | 0.9155 |
| TOTAL | 69.36 | 10 | <0.0001 |
Effects Response: Surv(days.to.event, outcome.bin) | |||||||
| Low | High | Δ | Effect | S.E. | Lower 0.95 | Upper 0.95 | |
|---|---|---|---|---|---|---|---|
| Total days supplied buprenorphine | 1 | 31 | 30 | -0.2258 | 0.06285 | -0.3490 | -0.1026 |
| Hazard Ratio | 1 | 31 | 30 | 0.7979 | 0.7054 | 0.9025 | |
Wald Statistics for Surv(days.to.event, outcome.bin) | |||
| χ2 | d.f. | P | |
|---|---|---|---|
| Total days supplied buprenorphine | 12.90 | 1 | 0.0003 |
| TOTAL | 12.90 | 1 | 0.0003 |
| time | probability |
|---|---|
| 2 | 0.9991667 |
| 8 | 0.9983333 |
| 19 | 0.9975000 |
| 32 | 0.9966667 |
| 45 | 0.9958333 |
| 70 | 0.9950000 |
| 97 | 0.9941667 |
| 101 | 0.9933333 |
| 111 | 0.9925000 |
| 125 | 0.9916667 |
| 131 | 0.9908333 |
| 173 | 0.9900000 |
| 177 | 0.9891667 |
| 217 | 0.9883333 |
| 222 | 0.9875000 |
| 240 | 0.9866667 |
| 244 | 0.9858333 |
| 258 | 0.9850000 |
| 261 | 0.9841667 |
| 270 | 0.9833333 |
| 274 | 0.9825000 |
| 287 | 0.9816667 |
| 310 | 0.9808333 |
| 323 | 0.9808333 |
| 27 | 0.9987952 |
| 35 | 0.9975904 |
| 77 | 0.9963855 |
| 87 | 0.9951807 |
| 91 | 0.9939759 |
| 101 | 0.9927711 |
| 118 | 0.9915663 |
| 138 | 0.9903614 |
| 147 | 0.9891566 |
| 166 | 0.9879518 |
| 193 | 0.9867470 |
| 213 | 0.9855422 |
| 215 | 0.9843373 |
| 217 | 0.9831325 |
| 245 | 0.9819277 |
| 270 | 0.9807229 |
| 272 | 0.9795181 |
| 281 | 0.9783133 |
| 295 | 0.9759036 |
| 300 | 0.9746988 |
| 301 | 0.9734940 |
| 319 | 0.9722892 |
| 323 | 0.9722892 |
| 7 | 0.9998575 |
| 8 | 0.9997150 |
| 10 | 0.9995725 |
| 17 | 0.9994300 |
| 18 | 0.9992875 |
| 34 | 0.9991451 |
| 35 | 0.9990026 |
| 38 | 0.9988601 |
| 41 | 0.9987176 |
| 42 | 0.9985751 |
| 43 | 0.9984326 |
| 45 | 0.9982901 |
| 47 | 0.9981476 |
| 52 | 0.9978626 |
| 59 | 0.9975777 |
| 60 | 0.9974352 |
| 61 | 0.9972927 |
| 63 | 0.9971502 |
| 65 | 0.9970077 |
| 66 | 0.9968652 |
| 69 | 0.9967227 |
| 72 | 0.9965802 |
| 75 | 0.9964377 |
| 93 | 0.9962952 |
| 95 | 0.9961528 |
| 110 | 0.9960103 |
| 112 | 0.9958678 |
| 118 | 0.9957253 |
| 120 | 0.9955828 |
| 121 | 0.9954403 |
| 128 | 0.9952978 |
| 138 | 0.9951553 |
| 140 | 0.9950128 |
| 144 | 0.9948703 |
| 151 | 0.9945854 |
| 153 | 0.9944429 |
| 156 | 0.9941579 |
| 169 | 0.9940154 |
| 171 | 0.9938729 |
| 175 | 0.9937304 |
| 178 | 0.9935879 |
| 180 | 0.9934454 |
| 181 | 0.9933029 |
| 182 | 0.9931604 |
| 184 | 0.9930180 |
| 185 | 0.9928755 |
| 188 | 0.9925905 |
| 199 | 0.9924480 |
| 204 | 0.9923055 |
| 208 | 0.9921630 |
| 211 | 0.9920205 |
| 213 | 0.9918780 |
| 214 | 0.9917355 |
| 215 | 0.9915930 |
| 216 | 0.9914506 |
| 220 | 0.9913081 |
| 223 | 0.9911656 |
| 228 | 0.9908806 |
| 229 | 0.9907381 |
| 233 | 0.9905956 |
| 235 | 0.9904531 |
| 236 | 0.9903106 |
| 239 | 0.9901681 |
| 240 | 0.9900256 |
| 242 | 0.9898832 |
| 246 | 0.9895982 |
| 247 | 0.9894557 |
| 250 | 0.9893132 |
| 253 | 0.9891707 |
| 254 | 0.9890282 |
| 261 | 0.9888857 |
| 262 | 0.9887432 |
| 263 | 0.9886007 |
| 265 | 0.9884583 |
| 267 | 0.9883158 |
| 268 | 0.9881733 |
| 271 | 0.9880308 |
| 274 | 0.9878883 |
| 275 | 0.9877458 |
| 279 | 0.9876033 |
| 287 | 0.9874608 |
| 289 | 0.9873183 |
| 290 | 0.9871758 |
| 296 | 0.9870333 |
| 298 | 0.9867484 |
| 302 | 0.9866059 |
| 304 | 0.9864634 |
| 305 | 0.9863209 |
| 308 | 0.9860359 |
| 310 | 0.9858934 |
| 313 | 0.9857509 |
| 316 | 0.9856084 |
| 321 | 0.9854659 |
| 323 | 0.9854659 |
Call:
survdiff(formula = Surv(days.to.event, outcome.bin) ~ moud.both3div,
data = moud)
N Observed Expected (O-E)^2/E (O-E)^2/V
moud.both3div=Only pre 1200 23 19.6 0.597 0.688
moud.both3div=Only post 830 23 13.5 6.654 7.324
moud.both3div=Both pre and post 7018 102 114.9 1.449 6.478
Chisq= 8.7 on 2 degrees of freedom, p= 0.01
Effects Response: Surv(days.to.event, outcome.bin) | |||||||
| Low | High | Δ | Effect | S.E. | Lower 0.95 | Upper 0.95 | |
|---|---|---|---|---|---|---|---|
| Total days supplied MOUD (method 3) | 1 | 31 | 30 | -0.124800 | 0.09117 | -0.303500 | 0.05387 |
| Hazard Ratio | 1 | 31 | 30 | 0.882700 | 0.738200 | 1.05500 | |
| Year of delivery | 2016 | 2018 | 2 | 0.348900 | 0.07889 | 0.194300 | 0.50350 |
| Hazard Ratio | 2016 | 2018 | 2 | 1.418000 | 1.214000 | 1.65500 | |
| Age at delivery | 27 | 31 | 4 | -0.061480 | 0.07178 | -0.202200 | 0.07921 |
| Hazard Ratio | 27 | 31 | 4 | 0.940400 | 0.816900 | 1.08200 | |
| Number of Gestation weeks | 39 | 37 | -2 | 0.119800 | 0.06176 | -0.001211 | 0.24090 |
| Hazard Ratio | 39 | 37 | -2 | 1.127000 | 0.998800 | 1.27200 | |
| MOUD receipt timing --- Only pre:Both pre and post | 3 | 1 | -0.004661 | 0.30270 | -0.597900 | 0.58850 | |
| Hazard Ratio | 3 | 1 | 0.995300 | 0.550000 | 1.80100 | ||
| MOUD receipt timing --- Only post:Both pre and post | 3 | 2 | 0.271700 | 0.31820 | -0.352000 | 0.89540 | |
| Hazard Ratio | 3 | 2 | 1.312000 | 0.703300 | 2.44800 | ||
| Route of delivery --- Cesarean:Vaginal | 2 | 1 | -0.016230 | 0.17750 | -0.364200 | 0.33170 | |
| Hazard Ratio | 2 | 1 | 0.983900 | 0.694800 | 1.39300 | ||
| Combined pain --- No:Yes | 2 | 1 | 0.257400 | 0.18600 | -0.107300 | 0.62200 | |
| Hazard Ratio | 2 | 1 | 1.294000 | 0.898300 | 1.86300 | ||
| Alcohol or other substance use --- Yes:No | 1 | 2 | 0.195100 | 0.17040 | -0.138900 | 0.52900 | |
| Hazard Ratio | 1 | 2 | 1.215000 | 0.870300 | 1.69700 | ||
| Benzodiazepine or anticonvulsant use --- Yes:No | 1 | 2 | 0.297500 | 0.21190 | -0.117900 | 0.71290 | |
| Hazard Ratio | 1 | 2 | 1.347000 | 0.888800 | 2.04000 | ||
| Anxiety and depression combined --- Yes:No | 1 | 2 | 0.527900 | 0.17940 | 0.176300 | 0.87950 | |
| Hazard Ratio | 1 | 2 | 1.695000 | 1.193000 | 2.41000 | ||
| Maternal morbidity --- Yes:No | 1 | 2 | -0.037990 | 0.35210 | -0.728200 | 0.65220 | |
| Hazard Ratio | 1 | 2 | 0.962700 | 0.482800 | 1.92000 | ||
Wald Statistics for Surv(days.to.event, outcome.bin) | |||
| χ2 | d.f. | P | |
|---|---|---|---|
| MOUD receipt timing | 1.08 | 2 | 0.5841 |
| Total days supplied MOUD (method 3) | 1.88 | 1 | 0.1708 |
| Year of delivery | 19.54 | 1 | <0.0001 |
| Age at delivery | 0.73 | 1 | 0.3913 |
| Route of delivery | 0.01 | 1 | 0.9272 |
| Number of Gestation weeks | 3.77 | 1 | 0.0521 |
| Combined pain | 1.91 | 1 | 0.1665 |
| Alcohol or other substance use | 1.31 | 1 | 0.2521 |
| Benzodiazepine or anticonvulsant use | 1.97 | 1 | 0.1601 |
| Anxiety and depression combined | 8.65 | 1 | 0.0033 |
| Maternal morbidity | 0.01 | 1 | 0.9140 |
| TOTAL | 69.00 | 12 | <0.0001 |
Effects Response: Surv(days.to.event, outcome.bin) | |||||||
| Low | High | Δ | Effect | S.E. | Lower 0.95 | Upper 0.95 | |
|---|---|---|---|---|---|---|---|
| Year of delivery | 2016 | 2018 | 2 | 0.35050 | 0.07832 | 0.197000 | 0.5040 |
| Hazard Ratio | 2016 | 2018 | 2 | 1.42000 | 1.218000 | 1.6550 | |
| Age at delivery | 27 | 31 | 4 | -0.06796 | 0.07223 | -0.209500 | 0.0736 |
| Hazard Ratio | 27 | 31 | 4 | 0.93430 | 0.811000 | 1.0760 | |
| Number of Gestation weeks | 39 | 37 | -2 | 0.12390 | 0.06132 | 0.003695 | 0.2441 |
| Hazard Ratio | 39 | 37 | -2 | 1.13200 | 1.004000 | 1.2760 | |
| MOUD receipt timing --- Only pre:Both pre and post | 3 | 1 | 0.24200 | 0.23080 | -0.210400 | 0.6943 | |
| Hazard Ratio | 3 | 1 | 1.27400 | 0.810300 | 2.0020 | ||
| MOUD receipt timing --- Only post:Both pre and post | 3 | 2 | 0.57760 | 0.23190 | 0.123100 | 1.0320 | |
| Hazard Ratio | 3 | 2 | 1.78200 | 1.131000 | 2.8070 | ||
| Route of delivery --- Cesarean:Vaginal | 2 | 1 | -0.02482 | 0.17700 | -0.371700 | 0.3220 | |
| Hazard Ratio | 2 | 1 | 0.97550 | 0.689600 | 1.3800 | ||
| Combined pain --- No:Yes | 2 | 1 | 0.25800 | 0.18610 | -0.106800 | 0.6228 | |
| Hazard Ratio | 2 | 1 | 1.29400 | 0.898700 | 1.8640 | ||
| Alcohol or other substance use --- Yes:No | 1 | 2 | 0.21430 | 0.17050 | -0.119800 | 0.5484 | |
| Hazard Ratio | 1 | 2 | 1.23900 | 0.887100 | 1.7310 | ||
| Benzodiazepine or anticonvulsant use --- Yes:No | 1 | 2 | 0.29820 | 0.21190 | -0.117200 | 0.7135 | |
| Hazard Ratio | 1 | 2 | 1.34700 | 0.889400 | 2.0410 | ||
| Anxiety and depression combined --- Yes:No | 1 | 2 | 0.52590 | 0.17920 | 0.174700 | 0.8770 | |
| Hazard Ratio | 1 | 2 | 1.69200 | 1.191000 | 2.4040 | ||
| Maternal morbidity --- Yes:No | 1 | 2 | -0.04240 | 0.35190 | -0.732200 | 0.6474 | |
| Hazard Ratio | 1 | 2 | 0.95850 | 0.480900 | 1.9110 | ||
Wald Statistics for Surv(days.to.event, outcome.bin) | |||
| χ2 | d.f. | P | |
|---|---|---|---|
| MOUD receipt timing | 6.55 | 2 | 0.0378 |
| Year of delivery | 20.01 | 1 | <0.0001 |
| Age at delivery | 0.89 | 1 | 0.3463 |
| Route of delivery | 0.02 | 1 | 0.8885 |
| Number of Gestation weeks | 4.09 | 1 | 0.0432 |
| Combined pain | 1.92 | 1 | 0.1657 |
| Alcohol or other substance use | 1.58 | 1 | 0.2086 |
| Benzodiazepine or anticonvulsant use | 1.98 | 1 | 0.1591 |
| Anxiety and depression combined | 8.61 | 1 | 0.0033 |
| Maternal morbidity | 0.01 | 1 | 0.9040 |
| TOTAL | 68.51 | 11 | <0.0001 |
Effects Response: Surv(days.to.event, outcome.bin) | |||||||
| Low | High | Δ | Effect | S.E. | Lower 0.95 | Upper 0.95 | |
|---|---|---|---|---|---|---|---|
| Total days supplied buprenorphine | 1 | 31 | 30 | -0.151300 | 0.09334 | -0.33420 | 0.03167 |
| Hazard Ratio | 1 | 31 | 30 | 0.859600 | 0.71590 | 1.03200 | |
| Year of delivery | 2014 | 2018 | 4 | 0.728200 | 0.16020 | 0.41420 | 1.04200 |
| Hazard Ratio | 2014 | 2018 | 4 | 2.071000 | 1.51300 | 2.83600 | |
| Age at delivery | 25 | 35 | 10 | -0.142200 | 0.18150 | -0.49800 | 0.21350 |
| Hazard Ratio | 25 | 35 | 10 | 0.867400 | 0.60770 | 1.23800 | |
| Number of Gestation weeks | 37 | 39 | 2 | -0.124100 | 0.06054 | -0.24280 | -0.00545 |
| Hazard Ratio | 37 | 39 | 2 | 0.883300 | 0.78450 | 0.99460 | |
| MOUD receipt timing --- Only pre:Both pre and post | 3 | 1 | -0.004516 | 0.30670 | -0.60570 | 0.59670 | |
| Hazard Ratio | 3 | 1 | 0.995500 | 0.54570 | 1.81600 | ||
| MOUD receipt timing --- Only post:Both pre and post | 3 | 2 | 0.372200 | 0.32520 | -0.26510 | 1.01000 | |
| Hazard Ratio | 3 | 2 | 1.451000 | 0.76710 | 2.74400 | ||
| Route of delivery --- Cesarean:Vaginal | 2 | 1 | -0.080810 | 0.18050 | -0.43460 | 0.27300 | |
| Hazard Ratio | 2 | 1 | 0.922400 | 0.64750 | 1.31400 | ||
| Combined pain --- No:Yes | 2 | 1 | 0.257000 | 0.18710 | -0.10970 | 0.62380 | |
| Hazard Ratio | 2 | 1 | 1.293000 | 0.89610 | 1.86600 | ||
| Alcohol or other substance use --- Yes:No | 1 | 2 | 0.271400 | 0.17210 | -0.06591 | 0.60860 | |
| Hazard Ratio | 1 | 2 | 1.312000 | 0.93620 | 1.83800 | ||
| Benzodiazepine or anticonvulsant use --- Yes:No | 1 | 2 | 0.308900 | 0.21260 | -0.10780 | 0.72560 | |
| Hazard Ratio | 1 | 2 | 1.362000 | 0.89780 | 2.06600 | ||
| Anxiety and depression combined --- Yes:No | 1 | 2 | 0.532400 | 0.18040 | 0.17890 | 0.88590 | |
| Hazard Ratio | 1 | 2 | 1.703000 | 1.19600 | 2.42500 | ||
| Maternal morbidity --- Yes:No | 1 | 2 | -0.040000 | 0.35290 | -0.73160 | 0.65160 | |
| Hazard Ratio | 1 | 2 | 0.960800 | 0.48110 | 1.91900 | ||
Wald Statistics for Surv(days.to.event, outcome.bin) | |||
| χ2 | d.f. | P | |
|---|---|---|---|
| MOUD receipt timing | 1.94 | 2 | 0.3790 |
| Total days supplied buprenorphine | 2.63 | 1 | 0.1049 |
| Year of delivery | 20.62 | 1 | <0.0001 |
| Age at delivery | 0.61 | 1 | 0.4330 |
| Route of delivery | 0.20 | 1 | 0.6546 |
| Number of Gestation weeks | 4.21 | 1 | 0.0401 |
| Combined pain | 1.89 | 1 | 0.1696 |
| Alcohol or other substance use | 2.49 | 1 | 0.1146 |
| Benzodiazepine or anticonvulsant use | 2.12 | 1 | 0.1458 |
| Anxiety and depression combined | 8.70 | 1 | 0.0032 |
| Maternal morbidity | 0.01 | 1 | 0.9096 |
| TOTAL | 75.64 | 12 | <0.0001 |
Effects Response: Surv(days.to.event, outcome.bin) | |||||||
| Low | High | Δ | Effect | S.E. | Lower 0.95 | Upper 0.95 | |
|---|---|---|---|---|---|---|---|
| Year of delivery | 2014 | 2018 | 4 | 0.73330 | 0.15890 | 0.42180 | 1.0450 |
| Hazard Ratio | 2014 | 2018 | 4 | 2.08200 | 1.52500 | 2.8430 | |
| Age at delivery | 25 | 35 | 10 | -0.16150 | 0.18280 | -0.51970 | 0.1967 |
| Hazard Ratio | 25 | 35 | 10 | 0.85090 | 0.59470 | 1.2170 | |
| Number of Gestation weeks | 37 | 39 | 2 | -0.12930 | 0.06002 | -0.24700 | -0.0117 |
| Hazard Ratio | 37 | 39 | 2 | 0.87870 | 0.78120 | 0.9884 | |
| MOUD receipt timing --- Only pre:Both pre and post | 3 | 1 | 0.29380 | 0.23160 | -0.16010 | 0.7477 | |
| Hazard Ratio | 3 | 1 | 1.34200 | 0.85200 | 2.1120 | ||
| MOUD receipt timing --- Only post:Both pre and post | 3 | 2 | 0.74020 | 0.23730 | 0.27510 | 1.2050 | |
| Hazard Ratio | 3 | 2 | 2.09600 | 1.31700 | 3.3370 | ||
| Route of delivery --- Cesarean:Vaginal | 2 | 1 | -0.09333 | 0.18000 | -0.44620 | 0.2595 | |
| Hazard Ratio | 2 | 1 | 0.91090 | 0.64010 | 1.2960 | ||
| Combined pain --- No:Yes | 2 | 1 | 0.25760 | 0.18730 | -0.10950 | 0.6246 | |
| Hazard Ratio | 2 | 1 | 1.29400 | 0.89630 | 1.8670 | ||
| Alcohol or other substance use --- Yes:No | 1 | 2 | 0.29550 | 0.17270 | -0.04307 | 0.6341 | |
| Hazard Ratio | 1 | 2 | 1.34400 | 0.95780 | 1.8850 | ||
| Benzodiazepine or anticonvulsant use --- Yes:No | 1 | 2 | 0.31000 | 0.21260 | -0.10680 | 0.7268 | |
| Hazard Ratio | 1 | 2 | 1.36300 | 0.89870 | 2.0680 | ||
| Anxiety and depression combined --- Yes:No | 1 | 2 | 0.53030 | 0.18020 | 0.17710 | 0.8834 | |
| Hazard Ratio | 1 | 2 | 1.69900 | 1.19400 | 2.4190 | ||
| Maternal morbidity --- Yes:No | 1 | 2 | -0.04663 | 0.35260 | -0.73770 | 0.6444 | |
| Hazard Ratio | 1 | 2 | 0.95440 | 0.47820 | 1.9050 | ||
Wald Statistics for Surv(days.to.event, outcome.bin) | |||
| χ2 | d.f. | P | |
|---|---|---|---|
| MOUD receipt timing | 10.20 | 2 | 0.0061 |
| Year of delivery | 21.27 | 1 | <0.0001 |
| Age at delivery | 0.78 | 1 | 0.3765 |
| Route of delivery | 0.27 | 1 | 0.6044 |
| Number of Gestation weeks | 4.66 | 1 | 0.0310 |
| Combined pain | 1.89 | 1 | 0.1690 |
| Alcohol or other substance use | 2.93 | 1 | 0.0870 |
| Benzodiazepine or anticonvulsant use | 2.13 | 1 | 0.1445 |
| Anxiety and depression combined | 8.65 | 1 | 0.0033 |
| Maternal morbidity | 0.02 | 1 | 0.8946 |
| TOTAL | 75.18 | 11 | <0.0001 |
| N | Overall | |
|---|---|---|
| (N=7125) | ||
| Year of delivery | 7125 (100.00) | |
| Median (interquartile range) | 2015 (2013—2017) | |
| Range | 2007—2018 | |
| Age at delivery | 7125 (100.00) | |
| Median (interquartile range) | 27 (24—30) | |
| Range | 17—44 | |
| Number of Gestation weeks | 7125 (100.00) | |
| Median (interquartile range) | 39 (37—39) | |
| Range | 21—42 | |
| Race | 7125 (100.00) | |
| American Indian or Alaska Native | 18/7125 (0.25) | |
| Asian or Pacific Islander | 9/7125 (0.13) | |
| Black of African American | 159/7125 (2.23) | |
| Other or Unknown | 47/7125 (0.66) | |
| White | 6892/7125 (96.73) | |
| Hispanic : Not Hispanic | 7120 (99.93) | 7063/7120 (99.20) |
| Race/Ethnicity combined | 7125 (100.00) | |
| Hispanic | 57/7125 (0.80) | |
| Non-Hispanic Asian | 8/7125 (0.11) | |
| Non-Hispanic Black | 158/7125 (2.22) | |
| Non-Hispanic Other | 49/7125 (0.69) | |
| Non-Hispanic White | 6853/7125 (96.18) | |
| Route of delivery : Vaginal | 7125 (100.00) | 4659/7125 (65.39) |
| Number of previous pregnancies | 6969 (97.81) | |
| Median (interquartile range) | 2 (1—3) | |
| Range | 0—23 | |
| Final outcome | 7125 (100.00) | |
| Death | 28/7125 (0.39) | |
| Overdose | 64/7125 (0.90) | |
| Loss of enrollment | 978/7125 (13.73) | |
| Censored | 6055/7125 (84.98) | |
| Final outcome (w/o all payer data) | 7125 (100.00) | |
| Death | 12/7125 (0.17) | |
| Overdose | 59/7125 (0.83) | |
| Loss of enrollment | 999/7125 (14.02) | |
| Censored | 6055/7125 (84.98) | |
| Total days supplied MOUD | 7125 (100.00) | |
| Median (interquartile range) | 122 (84—132) | |
| Range | 1—132 | |
| Total days supplied MOUD before delivery | 7125 (100.00) | |
| Median (interquartile range) | 90 (60—90) | |
| Range | 0—90 | |
| Total days supplied MOUD after delivery | 7125 (100.00) | |
| Median (interquartile range) | 42 (14—42) | |
| Range | 0—42 | |
| Total days supplied MOUD (method 2) | 7125 (100.00) | |
| Median (interquartile range) | 132 (84—132) | |
| Range | 1—132 | |
| Total days supplied MOUD before delivery (method 2) | 7125 (100.00) | |
| Median (interquartile range) | 90 (60—90) | |
| Range | 0—90 | |
| Total days supplied MOUD after delivery (method 2) | 7125 (100.00) | |
| Median (interquartile range) | 42 (36—42) | |
| Range | 0—42 | |
| Total days supplied MOUD (method 3) | 7125 (100.00) | |
| Median (interquartile range) | 88 (45—110) | |
| Range | 1—132 | |
| Total days supplied MOUD before delivery (method 3) | 7125 (100.00) | |
| Median (interquartile range) | 61 (30—76) | |
| Range | 0—90 | |
| Total days supplied MOUD after delivery (method 3) | 7125 (100.00) | |
| Median (interquartile range) | 29 (12—40) | |
| Range | 0—42 | |
| Avg dose pre-delivery (mg) | 7125 (100.00) | |
| Median (interquartile range) | 14.26 (8.00—16.00) | |
| Range | 0.00—50.00 | |
| Avg dose post-delivery (mg) | 7125 (100.00) | |
| Median (interquartile range) | 10.15 (4.00—16.00) | |
| Range | 0.00—380.00 | |
| Avg dose exposure (mg) | 7125 (100.00) | |
| Median (interquartile range) | 14.20 (9.98—16.00) | |
| Range | 0.00—380.00 | |
| Total days buprenorphine before delivery (method 3) | 6992 (98.13) | |
| Median (interquartile range) | 62.00 (30.00—77.00) | |
| Range | 0.00—90.00 | |
| Total days buprenorphine after delivery (method 3) | 6992 (98.13) | |
| Median (interquartile range) | 29.00 (12.00—40.00) | |
| Range | 0.00—42.00 | |
| Total days supplied buprenorphine | 6992 (98.13) | |
| Median (interquartile range) | 88.00 (46.00—110.00) | |
| Range | 1.00—132.00 | |
| Avg dose BUP pre-delivery (mg) | 6992 (98.13) | |
| Median (interquartile range) | 14.29 (8.00—16.00) | |
| Range | 0.00—40.00 | |
| Avg dose BUP post-delivery (mg) | 6992 (98.13) | |
| Median (interquartile range) | 9.60 (3.94—16.00) | |
| Range | 0.00—42.67 | |
| Avg dose BUP exposure (mg) | 6992 (98.13) | |
| Median (interquartile range) | 14.17 (9.77—16.00) | |
| Range | 0.00—42.67 | |
| Combined pain : Yes | 7125 (100.00) | 5769/7125 (80.97) |
| Schizophrenia or personality disorder : Yes | 7125 (100.00) | 502/7125 (7.05) |
| Alcohol or other substance use : Yes | 7125 (100.00) | 3299/7125 (46.30) |
| Benzodiazepine or anticonvulsant use : Yes | 7125 (100.00) | 1100/7125 (15.44) |
| Maternal morbidity : Yes | 7125 (100.00) | 571/7125 (8.01) |
| Anxiety and depression combined : Yes | 7125 (100.00) | 3016/7125 (42.33) |
| Back pain : Yes | 7125 (100.00) | 3033/7125 (42.57) |
| Med muscle relaxant use : Yes | 7125 (100.00) | 353/7125 (4.95) |
| Med NSAIDS : Yes | 7125 (100.00) | 4418/7125 (62.01) |
| Bipolar disorder : Yes | 7125 (100.00) | 691/7125 (9.70) |
| Depression : Yes | 7125 (100.00) | 2609/7125 (36.62) |
| Maternal morbidity : Yes | 7125 (100.00) | 571/7125 (8.01) |
| Med benzodiazepine use : Yes | 7125 (100.00) | 746/7125 (10.47) |
| Schizophrenia psychotic disorders : Yes | 7125 (100.00) | 377/7125 (5.29) |
| Tobacco use : Yes | 7125 (100.00) | 5036/7125 (70.68) |
| Dental pain : Yes | 7125 (100.00) | 270/7125 (3.79) |
| Alcohol use disorder : Yes | 7125 (100.00) | 458/7125 (6.43) |
| Other substance use : Yes | 7125 (100.00) | 3143/7125 (44.11) |
| Anxiety : Yes | 7125 (100.00) | 1153/7125 (16.18) |
| Fibromyalgia : Yes | 7125 (100.00) | 368/7125 (5.16) |
| Med anticonvulsant use : Yes | 7125 (100.00) | 427/7125 (5.99) |
| Personality disorder : Yes | 7125 (100.00) | 208/7125 (2.92) |
| CDC SVI overall percentile ranking of all 4 themes | 6610 (92.77) | |
| Median (interquartile range) | 0.57 (0.37—0.78) | |
| Range | 0.00—1.00 |
| n | missing | distinct | Info | Mean | pMedian | Gmd | .05 | .10 | .25 | .50 | .75 | .90 | .95 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 92 | 0 | 84 | 1 | 182.6 | 183 | 107.7 | 23.4 | 43.2 | 111.8 | 193.5 | 268.5 | 295.9 | 305.8 |
| n | missing | distinct | Info | Mean | pMedian | Gmd | .05 | .10 | .25 | .50 | .75 | .90 | .95 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28 | 0 | 27 | 1 | 163.7 | 163.5 | 118.1 | 24.60 | 37.10 | 58.75 | 174.50 | 267.75 | 283.70 | 293.25 |
| n | missing | distinct | Info | Mean | pMedian | Gmd | .05 | .10 | .25 | .50 | .75 | .90 | .95 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 64 | 0 | 61 | 1 | 190.9 | 195 | 102.7 | 29.25 | 51.80 | 123.75 | 213.00 | 268.50 | 300.10 | 309.10 |
Call: survfit(formula = Surv(days.to.event, outcome.bin) ~ 1, data = moud18)
n events median 0.95LCL 0.95UCL
[1,] 7125 92 NA NA NA
Min. 1st Qu. Median Mean 3rd Qu. Max.
2.0 111.0 184.0 181.1 268.0 323.0
| time | probability |
|---|---|
| 2 | 0.9998596 |
| 7 | 0.9997193 |
| 8 | 0.9995789 |
| 18 | 0.9994386 |
| 19 | 0.9992982 |
| 27 | 0.9991579 |
| 35 | 0.9990175 |
| 38 | 0.9988772 |
| 42 | 0.9987368 |
| 43 | 0.9985965 |
| 45 | 0.9984561 |
| 47 | 0.9983158 |
| 52 | 0.9980351 |
| 61 | 0.9978947 |
| 63 | 0.9977544 |
| 66 | 0.9976140 |
| 69 | 0.9974737 |
| 72 | 0.9973333 |
| 91 | 0.9971930 |
| 97 | 0.9970526 |
| 110 | 0.9969123 |
| 111 | 0.9967719 |
| 112 | 0.9966316 |
| 118 | 0.9964912 |
| 120 | 0.9963509 |
| 125 | 0.9962105 |
| 128 | 0.9960702 |
| 131 | 0.9959298 |
| 138 | 0.9956491 |
| 140 | 0.9955088 |
| 144 | 0.9953684 |
| 147 | 0.9952281 |
| 156 | 0.9950877 |
| 166 | 0.9949474 |
| 169 | 0.9948070 |
| 171 | 0.9946667 |
| 175 | 0.9945263 |
| 177 | 0.9943860 |
| 178 | 0.9942456 |
| 180 | 0.9941053 |
| 181 | 0.9939649 |
| 182 | 0.9938246 |
| 184 | 0.9936842 |
| 188 | 0.9935439 |
| 199 | 0.9934035 |
| 208 | 0.9932632 |
| 213 | 0.9929825 |
| 215 | 0.9928421 |
| 217 | 0.9925614 |
| 220 | 0.9924211 |
| 222 | 0.9922807 |
| 223 | 0.9921404 |
| 228 | 0.9920000 |
| 229 | 0.9918596 |
| 235 | 0.9917193 |
| 239 | 0.9915789 |
| 240 | 0.9912982 |
| 244 | 0.9911579 |
| 246 | 0.9910175 |
| 258 | 0.9908772 |
| 261 | 0.9907368 |
| 265 | 0.9905965 |
| 267 | 0.9904561 |
| 268 | 0.9903158 |
| 270 | 0.9900351 |
| 271 | 0.9898947 |
| 272 | 0.9897544 |
| 274 | 0.9896140 |
| 275 | 0.9894737 |
| 279 | 0.9893333 |
| 281 | 0.9891930 |
| 287 | 0.9890526 |
| 289 | 0.9889123 |
| 290 | 0.9887719 |
| 295 | 0.9884912 |
| 296 | 0.9883509 |
| 298 | 0.9882105 |
| 301 | 0.9880702 |
| 302 | 0.9879298 |
| 304 | 0.9877895 |
| 308 | 0.9876491 |
| 310 | 0.9873684 |
| 316 | 0.9872281 |
| 319 | 0.9870877 |
| 323 | 0.9870877 |
Effects Response: Surv(days.to.event, outcome.bin) | |||||||
| Low | High | Δ | Effect | S.E. | Lower 0.95 | Upper 0.95 | |
|---|---|---|---|---|---|---|---|
| Year of delivery | 2016 | 2018 | 2 | 0.28280 | 0.11690 | 0.05362 | 0.51190 |
| Hazard Ratio | 2016 | 2018 | 2 | 1.32700 | 1.05500 | 1.66900 | |
| Total days supplied MOUD (method 3) | 1 | 31 | 30 | -0.22850 | 0.07834 | -0.38200 | -0.07497 |
| Hazard Ratio | 1 | 31 | 30 | 0.79570 | 0.68250 | 0.92780 | |
| Age at delivery | 27 | 31 | 4 | -0.03437 | 0.09495 | -0.22050 | 0.15170 |
| Hazard Ratio | 27 | 31 | 4 | 0.96620 | 0.80210 | 1.16400 | |
| Number of Gestation weeks | 39 | 37 | -2 | 0.15990 | 0.07556 | 0.01176 | 0.30800 |
| Hazard Ratio | 39 | 37 | -2 | 1.17300 | 1.01200 | 1.36100 | |
| Route of delivery --- Cesarean:Vaginal | 2 | 1 | 0.18580 | 0.21990 | -0.24520 | 0.61670 | |
| Hazard Ratio | 2 | 1 | 1.20400 | 0.78260 | 1.85300 | ||
| Combined pain --- No:Yes | 2 | 1 | 0.26780 | 0.25060 | -0.22340 | 0.75900 | |
| Hazard Ratio | 2 | 1 | 1.30700 | 0.79980 | 2.13600 | ||
| Alcohol or other substance use --- Yes:No | 1 | 2 | -0.11430 | 0.21490 | -0.53560 | 0.30690 | |
| Hazard Ratio | 1 | 2 | 0.89200 | 0.58530 | 1.35900 | ||
| Benzodiazepine or anticonvulsant use --- Yes:No | 1 | 2 | 0.25130 | 0.26480 | -0.26770 | 0.77030 | |
| Hazard Ratio | 1 | 2 | 1.28600 | 0.76510 | 2.16000 | ||
| Anxiety and depression combined --- Yes:No | 1 | 2 | 0.56230 | 0.22270 | 0.12590 | 0.99870 | |
| Hazard Ratio | 1 | 2 | 1.75500 | 1.13400 | 2.71500 | ||
| Maternal morbidity --- Yes:No | 1 | 2 | -0.12120 | 0.42510 | -0.95440 | 0.71210 | |
| Hazard Ratio | 1 | 2 | 0.88590 | 0.38510 | 2.03800 | ||
Wald Statistics for Surv(days.to.event, outcome.bin) | |||
| χ2 | d.f. | P | |
|---|---|---|---|
| Year of delivery | 5.84 | 1 | 0.0157 |
| Total days supplied MOUD (method 3) | 8.51 | 1 | 0.0035 |
| Age at delivery | 0.13 | 1 | 0.7172 |
| Route of delivery | 0.71 | 1 | 0.3983 |
| Number of Gestation weeks | 4.48 | 1 | 0.0342 |
| Combined pain | 1.14 | 1 | 0.2853 |
| Alcohol or other substance use | 0.28 | 1 | 0.5945 |
| Benzodiazepine or anticonvulsant use | 0.90 | 1 | 0.3421 |
| Anxiety and depression combined | 6.37 | 1 | 0.0116 |
| Maternal morbidity | 0.08 | 1 | 0.7756 |
| TOTAL | 45.08 | 10 | <0.0001 |
Effects Response: Surv(days.to.event, outcome.bin) | |||||||
| Low | High | Δ | Effect | S.E. | Lower 0.95 | Upper 0.95 | |
|---|---|---|---|---|---|---|---|
| Total days supplied MOUD (method 3) | 1 | 31 | 30 | -0.2480 | 0.07827 | -0.4015 | -0.09463 |
| Hazard Ratio | 1 | 31 | 30 | 0.7803 | 0.6693 | 0.90970 | |
Wald Statistics for Surv(days.to.event, outcome.bin) | |||
| χ2 | d.f. | P | |
|---|---|---|---|
| Total days supplied MOUD (method 3) | 10.04 | 1 | 0.0015 |
| TOTAL | 10.04 | 1 | 0.0015 |
| N | Overall | |
|---|---|---|
| (N=9048) | ||
| Total days supplied MOUD (method 3) | 9048 (100.00) | |
| Median (interquartile range) | 88 (43—111) | |
| Range | 1—132 | |
| MOUD days exposure shifted approach | 9048 (100.00) | |
| Median (interquartile range) | 111 (65—126) | |
| Range | 1—132 |
Effects Response: Surv(days.to.event, outcome.bin) | |||||||
| Low | High | Δ | Effect | S.E. | Lower 0.95 | Upper 0.95 | |
|---|---|---|---|---|---|---|---|
| Year of delivery | 2016 | 2018 | 2 | 0.35000 | 0.07915 | 0.194800 | 0.50510 |
| Hazard Ratio | 2016 | 2018 | 2 | 1.41900 | 1.215000 | 1.65700 | |
| MOUD days exposure shifted approach | 1 | 31 | 30 | -0.14610 | 0.05798 | -0.259700 | -0.03245 |
| Hazard Ratio | 1 | 31 | 30 | 0.86410 | 0.771200 | 0.96810 | |
| Age at delivery | 27 | 31 | 4 | -0.06104 | 0.07196 | -0.202100 | 0.08000 |
| Hazard Ratio | 27 | 31 | 4 | 0.94080 | 0.817000 | 1.08300 | |
| Number of Gestation weeks | 39 | 37 | -2 | 0.12370 | 0.06192 | 0.002358 | 0.24510 |
| Hazard Ratio | 39 | 37 | -2 | 1.13200 | 1.002000 | 1.27800 | |
| Route of delivery --- Cesarean:Vaginal | 2 | 1 | -0.01795 | 0.17740 | -0.365700 | 0.32980 | |
| Hazard Ratio | 2 | 1 | 0.98220 | 0.693700 | 1.39100 | ||
| Combined pain --- No:Yes | 2 | 1 | 0.25950 | 0.18610 | -0.105200 | 0.62420 | |
| Hazard Ratio | 2 | 1 | 1.29600 | 0.900200 | 1.86700 | ||
| Alcohol or other substance use --- Yes:No | 1 | 2 | 0.19700 | 0.17080 | -0.137700 | 0.53170 | |
| Hazard Ratio | 1 | 2 | 1.21800 | 0.871400 | 1.70200 | ||
| Benzodiazepine or anticonvulsant use --- Yes:No | 1 | 2 | 0.29990 | 0.21200 | -0.115600 | 0.71530 | |
| Hazard Ratio | 1 | 2 | 1.35000 | 0.890800 | 2.04500 | ||
| Anxiety and depression combined --- Yes:No | 1 | 2 | 0.53120 | 0.18010 | 0.178200 | 0.88420 | |
| Hazard Ratio | 1 | 2 | 1.70100 | 1.195000 | 2.42100 | ||
| Maternal morbidity --- Yes:No | 1 | 2 | -0.03141 | 0.35210 | -0.721400 | 0.65860 | |
| Hazard Ratio | 1 | 2 | 0.96910 | 0.486100 | 1.93200 | ||
Wald Statistics for Surv(days.to.event, outcome.bin) | |||
| χ2 | d.f. | P | |
|---|---|---|---|
| Year of delivery | 19.52 | 1 | <0.0001 |
| MOUD days exposure shifted approach | 6.35 | 1 | 0.0117 |
| Age at delivery | 0.72 | 1 | 0.3958 |
| Route of delivery | 0.01 | 1 | 0.9195 |
| Number of Gestation weeks | 4.00 | 1 | 0.0455 |
| Combined pain | 1.95 | 1 | 0.1630 |
| Alcohol or other substance use | 1.33 | 1 | 0.2486 |
| Benzodiazepine or anticonvulsant use | 2.00 | 1 | 0.1568 |
| Anxiety and depression combined | 8.69 | 1 | 0.0032 |
| Maternal morbidity | 0.01 | 1 | 0.9289 |
| TOTAL | 65.88 | 10 | <0.0001 |
Effects Response: Surv(days.to.event, outcome.bin) | |||||||
| Low | High | Δ | Effect | S.E. | Lower 0.95 | Upper 0.95 | |
|---|---|---|---|---|---|---|---|
| MOUD days exposure shifted approach | 1 | 31 | 30 | -0.1698 | 0.05805 | -0.2836 | -0.05601 |
| Hazard Ratio | 1 | 31 | 30 | 0.8438 | 0.7531 | 0.94550 | |
Wald Statistics for Surv(days.to.event, outcome.bin) | |||
| χ2 | d.f. | P | |
|---|---|---|---|
| MOUD days exposure shifted approach | 8.55 | 1 | 0.0035 |
| TOTAL | 8.55 | 1 | 0.0035 |